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Abstract 
Background 
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder 
mainly affecting the elderly. Previously regarded a pure motor disease, PD is now 
considered a multisystem brain disease with various nonmotor aspects, including 
cognitive dysfunction. Mild cognitive impairment (MCI) is currently explored as a 
possible pre-dementia stage in patients with PD. Little is known about the pathology 
underlying MCI in PD. A full characterization of the various aspects of MCI in PD 
would be of great value in the search for prognostic factors and potential preventive 
treatments for disabling dementia in patients with PD. 
 
Volumetric brain magnetic resonance imaging (MRI) is increasingly used in research 
aiming to find the biological basis for various neurodegenerative diseases, atrophy 
regarded as the end stage of neurodegeneration. In PD, studies have shown brain 
atrophy in patients presenting with dementia. A few studies reported loss of brain 
tissue of midbrain and mesocortex in advanced stage patients with PD and MCI, but 
no previous study has investigated possible brain atrophy in newly diagnosed patients 
with PD and MCI. 
 
White matter hyperintensities (WMH) are high signal changes in T2- weighted brain 
MRI scans as a consequence of vascular damage. WMH has been linked to cognitive 
dysfunction in both normal aging and neurodegenerative disease, e.g. Alzheimer’s 
disease. Controlling vascular risk factors resulting in WMH might thus protect 
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against dementia and other forms of cognitive impairments. Earlier works on WMH 
in PD are conflicting, but a previous study indicated that WMH load is increased in 
demented patients with advanced PD. The role of WMH in patients with early PD 
and MCI is unknown.  
 
Objective 
The primary aim of this thesis was to test the hypothesis that cognitive impairment in 
newly diagnosed PD is related to atrophy and/or WMH changes in the brain. 
 
Methods 
Included subjects are all part of the Norwegian ParkWest study. The ParkWest study 
is a prospective multicentre cohort study of patients with incident PD from western 
and southern Norway, caregivers and a control group consisting of age and sex 
matched normal controls. An MRI examination was part of the baseline study 
evaluation and was conducted in 182 patients with PD and 109 controls.  
 
By widely used and validated quantitative MRI analysing methods, we performed 
volumetric global and regional brain segmentation and WMH quantification.  
 
WMH load was estimated by a semi-automated local threshold technique. Total 
volume and regional distribution of WMH in patients with newly diagnosed PD were 
compared with findings in age-matched controls. The impact of WMH on cognitive 
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test performance was investigated both in the unselected PD sample and according to 
MCI classification.  
 
Global brain MRI atrophy measures were whole brain and total 
gray/white/cerebrospinal fluid volumes calculated using SIENAX software. Regional 
atrophy was investigated in a subgroup of patients from one centre using voxel-based 
morphometry (VBM) and the FreeSurfer software. Ventricular volumes were also 
calculated. 
 
Neuropsychological tests were chosen to minimize the impact of impaired motor 
skills and assessed memory, visuospatial and attention-executive domains.  Non-
demented patients with an observed age-and education corrected z-score deviating 
more than -1.5 standard deviations from the expected z-score (based on the test 
performance of controls) in at least one cognitive domain, were classified as having 
MCI. 
 
Results 
Our investigations of global brain MRI atrophy parameters (whole brain, total gray 
and white matter volume) did not show any significant difference between newly 
diagnosed patients with PD and controls and were not significant predictors of 
cognitive performance. Furthermore, neither total WMH volume nor regional 
distribution of WMH was significantly different between patients and controls, 
irrespectively if patients were presenting MCI. Regional gray matter atrophy 
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analyses, volume of subcortical gray matter structures and ventricular volume 
measures may indicate enlargement of fourth, third and left inferior lateral ventricles, 
but no cortical atrophy, as a sign of MCI in early PD. 
 
Conclusion 
Based on these studies, WMH do not seem to play a significant role as a 
neurobiological factor in the cognitive dysfunctions of incident patients with PD. 
Volume studies could indicate a possible role of atrophy in brainstem, midbrain and 
temporal regions, but this needs to be explored further in future larger studies.  
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1. Introduction 
 
Parkinson’s disease (PD) is a common neurodegenerative disease mainly affecting 
the elderly. With industrialization and the socioeconomic progresses in the past 
century, population structures are changing. As a consequence of increased 
prevalence of diseases typical of older age, the potential impact of degenerative brain 
disorders becomes even more prominent in both human and economic terms. A better 
understanding of such diseases is important for patients, caregivers and physicians 
involved, but it is also highly relevant for the general society given all the challenges 
ahead. 
 
Despite recent advances, much is still unknown regarding pathogenesis and 
progression of cognitive impairments in PD. The work included in this thesis aims to 
add more pieces to the puzzle by the use of conventional brain magnetic resonance 
imaging (MRI). The first general section will give a brief overview of PD and basic 
MRI principles and analyzing methods, followed by a description of previous work 
on volumetric MRI and cognitive aspects of the disease. The rest of the thesis 
describes and discuss structural MRI findings and cognitive impairment in patients 
with newly diagnosed PD, results obtained from MRI data analyses in the Norwegian 
ParkWest study. 
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1.1 Parkinson’s disease 
 
1.1.1 From shaking palsy to multisystem brain disease 
PD was first described in 1817 by James Parkinson in his publication “An essay on 
the shaking palsy”.1,2 The essay consisted of six case reports with detailed 
observations of patients with symptoms of “Involuntary tremulous motion” and “A 
propensity to bend the trunk forwards and to pass from a walking to a running pace”. 
Half a century later, Charcot and colleagues further distinguished the disease and 
suggested the term “Parkinson’s disease”. The pathological hallmark of the disease, 
the Lewy bodies, was first described in 1913, and the biochemical basis of the disease 
and advances in dopaminergic treatment was investigated in the 1960’s.3 In the 
following years, new knowledge has especially evolved in the genetic and molecular 
basis of PD, but also clinically with respect to the various nonmotor aspects of the 
disease. 
 
James Parkinson described the shaking palsy with “the senses and intellect being 
uninjured” and for a long time PD was regarded a pure motor disease and with a 
distinct clinical syndrome called parkinsonism. Recent works have shown that PD 
now must be regarded a multisystem brain disease with widespread and 
heterogeneous effects on the nervous system resulting in various clinical 
expressions.4,5 
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Nowadays PD is considered a chronic, progressive and systemic neurological disease 
with a number of “non-dopaminergic” symptoms in addition to its well established 
motor characteristics tremor, rigidity, bradykinesi and postural instability. Cognitive 
impairment, olfactory dysfunction, dysautonomia, sleep disturbances and 
neuropsychiatric symptoms are all known possible features of established disease. At 
present many of these nonmotor symptoms are receiving major attention as possible 
signs of presymptomatic PD,6 and intensive efforts are warranted to investigate the 
basis for PD pathology beyond the nigrostriatal dopamine pathway.7  
 
1.1.2 Epidemiology 
Idiopathic PD is the second most common neurodegenerative disorder after 
Alzheimer’s disease (AD).8 PD affects about 1 % of the population over the age of 
60, has increasing prevalence with age and about 4 % of people in the highest age 
groups suffer from PD.8 
 
Prevalence studies are reporting different numbers, but in general community based 
surveys in Europe found the prevalence between 100 and 200 per 100.000 
inhabitants. Age-standardized incidence rated range from 8.6 to 19.0 per 100.000.9 In 
the Norwegian Park West study, an age-standardized incidence of 12.6 per 100.000 
was calculated.10 Most studies report incident PD more common in men and in rural 
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districts.11 The Norwegian Park West study found an overall male to female ratio of 
1.58.10 
 
Based on published prevalence studies, Dorsey et al.12 estimated that in Western 
Europe’s 5 and the world’s 10 most populous nations the number of individuals 
diagnosed with PD over 50 years of age will double from 4.1-4.6 million in 2005 to 
8.7-9.3 million by 2030. 
 
1.1.3 Aetiology and risk factors 
In the majority of PD cases, no obvious cause for the disease is found. PD is now 
regarded a multifactorial disease, resulting from combinations of hereditary, 
environmental and endogenous risk factors, but clear causative factors and their 
relationship with possible susceptibility genes are yet to be explored.8 
 
A relationship between age and PD is reported, and the disease is rare in people under 
50 years of age.8 Studies have found that advancing age is associated with faster rate 
of motor impairment, decreased levodopa responsiveness, more severe gait and 
postural impairment and more severe cognitive dysfunction.13 Gilberto Levy 
proposed a model for the relationship between PD and aging consisting of three 
elements.13 The first element suggests a superposition of a topographic gradient of 
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disease related neuronal loss in brainstem and basal forebrain structures and an aging-
related temporal gradient. Furthermore, in PD, unlike other neurodegenerative 
diseases, advancing age, rather than disease duration, is the most important 
determinant of clinical progression. Finally, there is an interaction between the effects 
of age and disease on non-dopaminergic structures. A recent pathology study 
suggested that two age-related factors are important in the pathological progression in 
PD: age at onset of symptoms and age-related Alzheimer-type pathology.14 
 
1.1.3.1 Non-genetic risk factors 
Many epidemiological studies have investigated the role of pesticides in the 
pathogenesis of PD, and exposure to such toxins has been found to double the risk of 
developing the disease. Reports on welding and exposure to various heavy metals are 
more inconclusive.8 There is an inverse association between smoking and PD, and 
coffee consumption seems to decrease the risk of PD.8 Dietary factors such as 
antioxidants and fatty acids are under investigation, but consistent results are missing. 
The role of inflammation in the pathogenesis of PD is currently not known.8 
 
1.1.3.2 Genetic risk factors 
A meta-analysis showed that the relative risk of PD when having a first-degree 
relative with PD versus no first degree relative with PD was about 3, and concluded 
that family aggregation of PD is strong and unlikely to be due to chance.15 Genetic 
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insights in the last decades have expanded the view upon PD as, at least in part, a 
hereditary disease.  
 
Distinct genetic subgroups of the disease have been identified and provide arguments 
for PD not being a single clinical entity.4 Still, monogenetic forms constitute less than 
10 % of patients with PD, and studies focusing on interaction between susceptibility 
genes and other factors are so far suffering from methodological weaknesses such as 
lack of statistical power.8 Our understanding of genetics in PD is further limited by 
several factors: the penetrance of mutations are often either reduced or unknown, 
clinical and pathological expressions are variable, and finally, presence of a genetic 
mutation indicates a risk for developing PD, but says nothing about timing of disease 
onset.16  
 
1.1.3.3 Vascular factors and idiopathic PD 
In AD, a role of vascular pathology in the development of cognitive decline is 
suggested.17 Risk factors of cerebrovascular lesions (e.g. ischemic and haemorrhagic 
stroke, white matter pathology, angiopathy) are among others diabetes mellitus, 
hypertension, smoking and hyperlipidemia. Many of these risk factors are reversible 
and might thus represent important targets for intervention aiming to prevent and treat 
highly disabling dementia. 
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Work regarding the relationship between cerebrovascular pathology and PD has 
showed conflicting results with some studies reporting increased frequencies of such 
events in PD18 and others claiming the opposite.19 A recent large observational study 
found increased risk of PD after a previous stroke, and the risk of first-time ischemic 
stroke in patients with newly diagnosed PD was about 1.5 to 2 times higher than in 
subjects without PD.18 This was in contrast to an earlier cross-sectional study 
indicating that prevalence of stroke in PD was reduced compared to controls.19  
 
With respect to the clinical impact of vascular pathology, a study on late onset PD 
showed that presence of minor stroke, diabetes mellitus and ischemic heart disease 
was significantly associated with more disabling disease,20 but a longitudinal study 
found that smoking status was not significantly associated with disease progression in 
PD.21 The cognitive impact of vascular disease in patients with PD is not established. 
A post-mortem study reported that cognitive impairment was only associated with 
severe vascular pathology,22 and a clinical observation study reported that established 
cerebrovascular risk factors were not associated with incident dementia in PD.23 The 
extent and impact of potentially treatable and preventable cerebrovascular pathology 
in PD is thus uncertain. More research is needed to clarify the importance of vascular 
brain pathology in the aetiology of both motor and nonmotor aspects of idiopathic 
PD. 
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The relationship between cerebrovascular disease and PD is complicated by various 
issues, and there are factors associated with PD potentially increasing or decreasing 
the risk of cerebrovascular disease: 1) A reduced prevalence of smokers in PD, 
smoking being a well known risk factor for vascular pathology, might explain lower 
frequencies of vascular pathology in PD.19 2) Hyperhomocysteinemia is a risk factor 
for vascular disease, and antiparkinsonian medication (levodopa) is associated with 
increased blood levels of homocysteine. This could possibly result in more 
cerebrovascular disease in patients with PD,24 although this was not confirmed in a 
recent study.25 3) Autonomic dysfunction is common in PD and might have effects on 
the cardiovascular system causing less vascular disease risk factors in PD.26   
 
Vascular parkinsonism is a clinical entity used to describe a condition where 
parkinsonism is caused by cerebral vascular disease. The diagnosis is considered 
when history includes repeated strokes and/or (related) stepwise progression of 
parkinsonism with compatible neuroradiological findings. In the Norwegian 
ParkWest study, 1.9 % of incident cases were re-diagnosed during follow-up with 
vascular parkinsonism. So far, there is no accepted precise definition of vascular 
parkinsonism, and it might be difficult to distinguish vascular parkinsonism from 
idiopathic PD. Both the vascular pathologies and PD are diseases of older age, and a 
recent paper argues that when signs and symptoms are typical for idiopathic PD, 
coincidence of the two conditions should be considered rather than vascular 
parkinsonism.27  
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1.1.4 Neuropathology  
The neuropathological hallmarks of PD are gliosis and cell loss in nigrostriatal 
neurons with the presence of Lewy pathology, and such findings are currently the 
gold standard for a diagnosis of PD.28 The resulting dopaminergic deficiency explains 
dysfunction of movement, behaviour, learning and emotions, but can not account for 
the full clinical picture seen in patients with PD.29  
 
Lewy pathology is a term for α-synuclein immunoreactive neural inclusions and 
consists of various eosinophilic inclusions in neuronal perikarya (Lewy bodies) in 
addition to inclusions of neuronal cell processes (Lewy neurittes).30 Lewy bodies are 
found in the brains of 10 % of healthy individuals over 60 years of age, and this is 
sometimes described as incidental Lewy body disease. A recent study suggests that 
this might represent pre-symptomatic PD,31 but the role of non-symptomatic Lewy 
bodies is not yet fully established. 
 
In 2003 Braak and colleagues presented a new classification system for the pathology 
of PD.32 Their hypothesis claims that the disease related pathology develops in a 
coherent sequence. In the initial two stages lesions involve the anterior olfactory 
nucleus, the dorsal motor nucleus of the IX/X nerves, the raphe nuclei and the 
reticular formation. In stages 3 and 4 pathology is confined to the brainstem and 
anteromedial temporal mesocortex. The principal characteristic of this stage is 
affection of the substantia nigra and initial clinical recognizable disease. Stages 5 and 
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6 consist of severe involvement of the brain, including neocortical areas. The six 
stages are illustrated in Figure 1.1. 
Several papers have argued against a unified disease progression as suggested in the 
Braak hypothesis.33,34 The staging system was recently validated, and 83 % of 
subjects showed a distribution of Lewy pathology according to the various stages. 
Notably 55 % of subjects in Braak’s stages 5 and 6 showed no sign of dementia 
Figure 1.1 
Progression of PD related pathology. Lesions initially occur in the dorsal IX/X motor nucleus and the 
various brain structures gradually become involved as indicated by the white arrows (left). The gradual 
decrease in shading intensity is indented to represent the topographic expansion of the lesions during 
the course of the disease. Simplified diagram (right) showing expansion of lesions (left to right: dm to 
fc) and the growing severity of overall severity (top to bottom: stages 1-6). dm= dorsal IX/X motor 
nucleus; co = coeruleus-subcoeruleus complex; sn= substantia nigra; mc=anteromedial temporal 
mesocortex; hc=high orden sensory association areas and prefrontal fields; fc=first order sensory 
association areas, premotor areas, as well as primary sensory and motor fields. Modified reprint from 
Braak et al.32 with permission from Elsevier.  
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despite widespread cortical affection.35 In a post mortem study, Halliday et al.36 
identified three distinct subgroups of patients with PD, findings that were not 
consistent with the Braak concept of a topographical distinct and progressive 
pathogenesis of the disease. Future studies, combining clinical, neuroimaging and, if 
available, pathological data, are needed for further validation of the Braak hypothesis. 
 
1.1.5 Clinical manifestations 
The clinical picture in PD is heterogenous.4,5 The following section aims to give a 
broad overview of the varied clinical manifestations of PD with special focus on 
findings in the early clinical recognisable stages of the disease. A newly published 
study found that both motor and nonmotor features in early PD predicted increased 
mortality risk, in particular postural instability gait difficulty, cognitive impairment 
and hallucinations.37 
 
 
 
1.1.5.1 Motor features 
The key motor manifestations of PD are typically unilateral in early disease, and 
become clinically evident when dopamine levels fall below 60 % in the contra lateral 
striatum.38 The four cardinal clinical signs of PD are tremor, rigidity, bradykinesi and 
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postural instability.28 These features are not specific for PD, but are also seen in 
parkinsonian disorders like Multiple System Atrophy, Progressive Supranuclear Palsy 
and vascular parkinsonism. Tremor is the most common motor symptom in PD and is 
seen in about 70 % of newly diagnosed patients.39 Axial symptoms are more rare in 
incident disease, but progress over time, and a postural gait instability dominated PD 
is in general associated with poorer prognostic outcome.5 It has been speculated in 
that this clinical subtype is a result of more extensive underlying pathology.37  
  
1.1.5.2 Premotor PD 
Lately, there is increasing focus on the premotor phase of PD. This phase of the 
disease is defined by the period, years or even decades, when various nonmotor 
symptoms arise preceding the classic motor symptoms PD.6 The nonmotor symptoms 
that are believed to be present in this very early stage of PD are olfactory dysfunction, 
dysautonomia (e.g. bladder dysfunction and constipation) and mood and sleep 
disturbances. Many of the symptoms could be explained by the Braak hypothesis,32 
but as mentioned above the concept of sequential development of Lewy pathology 
might not be unitary in all cases of sporadic PD.  
By recognizing these symptoms and, if possible, be able to diagnose premotor PD, 
one hopes to identify subjects at risk before symptomatic degeneration of 
dopaminergic neurons in substantia nigra has occurred. In the future, combined 
neuroimaging and for instance olfactory testing in relatives of patients with PD might 
serve as screening strategies to detect very early disease. The cost effectiveness and 
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clinical use of such screening tools are currently limited by the lack of effective 
treatments and knowledge of causative PD pathology.16  
 
1.1.5.3 Nonmotor symptoms 
Cognitive deficits, olfactory dysfunction, autonomic disturbances and various 
neuropsychiatric symptoms are all known nonmotor manifestations of PD.40 The 
most common neuropsychiatric symptoms are depression, anxiety, apathy, fatigue 
and psychosis (mainly visuo-perceptual symptoms).41 Previously often not 
appreciated, they are now integrated parts of our understanding of PD as a 
multisystem neurodegenerative brain disease. Many of the nonmotor symptoms 
associated with PD are considered to be caused by changes in non-dopaminergic 
transmitter systems,7 but the pathology underlying the nonmotor symptoms is 
debated. According to Braak,42 it can be explained by presence of Lewy pathology. 
The nonmotor symptoms often have a major impact on quality of life in patient with 
PD,43 and both clinical and academic efforts are important in understanding, 
diagnosing and treating these aspects of PD.  
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1.1.6 Cognitive impairment 
In this thesis, special attention will be given the cognitive deficits in PD. Cognitive 
dysfunctions are common in PD, and there is a wide range of severity from disabling 
dementia44 to less severe cognitive deficits not affecting daily life activities described 
as mild cognitive dementia (MCI).45  
 
The pathological basis for cognitive dysfunction in patients with PD is still 
controversial. Hypotheses include both neurotransmitter deficits (dopamine, 
serotonin, acetylcholine and noradrenalin) and cortical LB deposits.46,47 Several 
studies have also reported that Alzheimer-type changes are common and are likely to 
contribute to dementia in PD.44 Finally, cerebrovascular pathology might also be 
present in some subjects.22 
 
1.1.6.1 PD with dementia 
Dementia is a common feature of PD with estimated prevalence varying between 24 
and 31%.48 Patients with PD have a six-fold increased risk of developing dementia 
compared to non-demented controls.49 PD dementia (PDD) has a major impact on 
quality of life50 and mortality.51 PDD is an important risk factor for nursing home 
placement,52 and as a consequence of this, PDD has important health economic 
implications.  
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PD with and without dementia can be classified as Lewy body disorders characterized 
by defects in α-synulein metabolism and deposits of Lewy pathology. Another 
disease in this group of neurodegenerative disorders is Dementia with Lewy bodies 
(DLB). DLB is characterised clinically by dementia combined with idiopathic 
parkinsonism, persistent visual hallucinations, and cognitive fluctuations. DLB 
probably accounts for about 15-25 % of late-onset dementias, and is thus the second 
most common subgroup of degenerative dementias after AD.53 There is a continuing 
debate on whether PD, PDD and DLB diagnoses represent different disorders or are 
just different stages in a spectrum of Lewy body disorders. Per definition, dementia 
occurring before or within one year after parkinsonism is classified as DLB, whereas 
PDD is diagnosed if dementia occurs later than one year after onset of 
parkinsonism.54,55 Although these two syndromes share many clinical and 
pathological features, subtle differences also exist. In the Norwegian ParkWest Study, 
nine subjects with parkinsonism and initially diagnosed with PD were re-diagnosed 
as having DLB during follow up diagnostic procedures.10  
 
PDD typically involves a variety of cognitive domains including impaired attention, 
memory, visuospatial, constructional and executive functions, and deficits are found 
even in early disease stages. Neuropsychiatric symptoms like mood disturbances, 
hallucinations, delusions and apathy also occur in the majority of patients.44  
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The postural instability and gait difficulty motor subtype of PD have been found to be 
associated with a faster rate of cognitive decline. 56,57 Other risk factors for 
developing dementia are higher age, more advanced clinical disease stage and 
reduced cognitive ability.44,49 In the past few years the concept of MCI has received 
more attention as a possible pre-dementia stage, and many ongoing studies are trying 
to elaborate this possible very early stage of PDD.  If such a pre-dementia stage can 
be characterized and diagnosed, it will be of great value in the search for prognostic 
factors and possible preventive treatments. Knowledge of how to prevent or delay 
PDD would be very useful for patients and caregivers, but also have major public 
health benefits.  
 
1.1.6.2 MCI 
In the past decade, a variety of definitions for MCI in PD have been used, based on 
various study designs, cognitive test batteries and cut-off levels for test 
performance.58 MCI was originally a term used for description of  the transitional 
stage between normal cognitive functioning and AD,59 but MCI is now increasingly 
used for other types of disorders, e.g. PD. Still, clinical criteria for MCI in PD have 
not yet been established.45  
 
MCI in PD typically implies reduced visuospatial, executive and attentional functions 
contributing to impaired working memory, but deficits in memory are also 
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common.60,61 A study found MCI in about 30 % of patients with PD with intact global 
cognition based on Mini-Mental State performance (MMSE). Increasing age and 
disease severity, anti-anxiety medication use and daytime sleepiness were 
independent predictors of the cognitive impairment.61  
 
Studies on newly diagnosed patients report frequencies of MCI ranging from 19 to 36 
%.62-65 The variety of findings is probably related to the use of the different MCI 
classifications and neuropsychological test batteries. Furthermore, the recruitment 
strategies vary among studies, and thus different PD populations have been included. 
 
As mentioned, the presence of MCI in PD seems to identify patients with a high risk 
of developing dementia. A clinical observation study including patients with 
advanced PD found that executive dysfunctions predicted PDD 4 years later.66 A 
longitudinal 3.5 year follow-up study on incident PD reported that reduced 
performance on tests with more posterior cortical basis, along with non-tremor 
dominant motor subtype, were the most important clinical predictors of global 
cognitive decline. At follow-up, 57 % presented cognitive impairment and 10 % 
dementia57 A recently published longitudinal study of patients with early PD, found 
that 48 % of patients had developed cognitive impairment and 9 % were demented 
after 3 years of follow-up. Interestingly, in this study, none of the baseline 
characteristics predicted cognitive changes in newly diagnosed patients.67 
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1.1.7 Treatment of PD. 
The treatment of PD involves dopamine replacement therapy with L-dopa, and 
several dopamine agonists. Monoamine oxidase inhibitors are also in use. The latter 
has been shown to have a potential neuroprotective effect and might slow disease 
progression in addition to increased dopamine levels in the brain. Deep brain 
stimulation with implementation of electrodes can be helpful for selected patients 
especially in tremor dominant disease. 
 
As for cognitive symptoms, studies indicate that cholinergic drugs might be useful.68 
A recent small placebo-controlled study show promising results of glutaminergic 
drugs in PDD.69 
 
1.1.8 Diagnosis 
Parkinsonism is a clinical diagnosis defined by the presence of the cardinal symptoms 
of rigidity, bradykinesia, tremor and postural abnormalities. Parkinsonism can be 
found in various neurological diseases. The diagnosis of idiopathic PD is therefore 
often a challenge because the symptoms may be subtle at onset, and diagnostic errors 
include AD, DLB and atypical parkinsonian disorders such as Multiple System 
Atrophy and Progressive Supranuclear Palsy. A neuropathological study confirmed 
idiopathic PD in only 76 % of a cohort of 100 patients with clinical PD.70 The use of 
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strict diagnostic criteria has increased the accuracy of the clinical diagnosis in 
parkinsonian syndromes.71  
 
There are several diagnostic criteria in use; based on some combination of the 
cardinal motor signs and response to dopaminergic treatment. For the current thesis, 
we have applied the research criteria proposed by Gelb.28 The Gelb criteria 
distinguish between three levels of diagnostic confidence: possible, probable and 
definite.The diagnosis of definite PD requires histopathological confirmation. (Tables 
1, 2 and 3, from Gelb et al.28 ) 
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1.1.9 Diagnostic neuroimaging and PD 
Neuroimaging is not recommended for routine diagnostic use in PD by the Gelb 
criteria.28 In the decade that have passed since these criteria were introduced, the field 
of imaging in PD has evolved greatly, but PD has remained a clinical diagnose. 
 
Nuclear imaging provides at present the most sensitive tool for early diagnosis of PD 
and related disorders. Positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) can provide information regarding various 
neuron functions, functional metabolism and regional perfusion in the brain using 
transmitter specific tracers (e.g. dopamine tracers) or unspecific tracers such as 
glucose. Dopamine transporter imaging (DAT) is in clinical use using SPECT. Loss 
of dopamine transporter is a marker of reduced number of presynaptic neurons, and 
DAT-SPECT is suggested as a diagnostic tool in routine clinical practise.72 
  
Compared to the nuclear imaging techniques, structural imaging using MRI is in 
general more available, offers no ionizing radiation and is relatively cheap. With 
respect to MRI, there are no findings sensitive or specific for the diagnosis of PD. 
Patients with suspected idiopathic PD are referred for a scan mainly to exclude the 
various differential diagnoses associated with parkinsonism. Most previous 
conventional MRI studies have failed to find disease specific abnormalities in early 
PD, possibly due to limitation of techniques unable to detect the subtle pathology 
expected in these stages of the disease. The ability for routine MRI to differentiate 
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PD from controls is therefore modest.73 Recently proposed diagnostic tools are not 
validated and includes among others assessment of the substantia nigra 
degeneration,74 pathologic diffusion in the olfactory tract75 and high field MRI.76 The 
new and advanced techniques are promising for better detection of early PD related 
changes in the brain, but this needs further investigations.  
 
Another widely available and safe imaging modality is transcranial ultrasound. This 
technique has been used to evaluate the substantia nigra in patients with PD. 
Hyperechogenicity is found in up to 90 % of patients with idiopathic PD. Increased 
echo of the substantia nigra has been proposed as a potential risk marker for PD, but 
this is complicated due to the fact that this finding is seen also in about 10 % of 
controls. The role of transcranial ultrasound in established disease is limited as it is 
shown that the finding is not associated with disease progression or clinical severity.77 
  
Potential biomarkers for PD are currently a hot topic.78 Such biomarkers may be used 
as surrogate end points in clinical drug trials in established disease, but are also 
important in preclinical stages in order to prevent disease in subjects at risk. Until 
recently, the substantia nigra has received the majority of attention in the search for a 
neuroimaging biomarker.79 The small size of this nucleus and many difficulties in 
depicting its exact boundaries by current imaging standards, in addition to the fact 
that clinical expression is found with extensive degeneration, may limit the usefulness 
of substantia nigra as a site for evaluating disease progression in PD. Advances in 
techniques and the new knowledge about PD being a more widespread disease has 
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resulted in new search strategies. Lately, and among many others, both serial 
volumetric MRI80 and metabolic approaches81 have been suggested as potential 
markers of disease progression. 
 
Despite its limited use in clinical diagnostic practise, neuroimaging plays an 
important role in academic settings. The currently used gold standard in PD research 
is neuropathology, but such studies often only describe end stage disease and merely 
provide cross-sectional information. Contrary to this, neuroimaging offers unique in 
vivo representation of the disease and can also be used in longitudinal designs. 
Adequate neuroimaging techniques may therefore provide an understanding of PD 
pathology in the various disease stages, its clinical correlates and the pathological 
progression over time. Extensive collaborative studies, combining clinical, 
pathological, genetic, biochemical and imaging findings, are needed in order to 
achieve such an understanding.  
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1.2 Magnetic Resonance Imaging (MRI) 
 
1.2.1 History of MRI 
Following the discoveries of X-rays by Roentgen in 1895 and radioactivity and 
radium by Becquerel and the Curies in 1896, the basic techniques of radiology were 
established and developed. Half a century later, in 1938, Rabi was the first to describe 
the physical phenomenon of nuclear magnetic resonance (NMR), a discovery that led 
to the 1944 Nobel Prize in Physics (http://nobelprize.org). Important breakthroughs 
leading to current MRI technology, were done in the years after the World War II. In 
1945 Bloch, and independently Purcell and Pound, discovered the principles of 
nuclear induction. They showed that one can detect a signal (a voltage in a coil) when 
a sample is placed in a magnetic field and exposed with a radiofrequency (RF) energy 
(a RF pulse) of a certain frequency (the Larmor frequency). The detected signal was a 
result of interaction between nuclei in the sample and the magnetic field. In 1952, 
Purcell and Bloch received the Nobel Prize in Physics.82 NMR was further developed 
as a laboratory spectroscopic technique used for examination of molecular structures 
in compounds, and great scientists involved in this work were also later honoured 
with Nobel Prizes (Bloembergen 1981, Ramsey 1989, Ernst 1991, Wüthrich 2002).82 
The clinical use of nuclear magnetic resonance imaging (NMRI) was initiated by the 
chemist Paul Lauterbur in 1973, and further developed by a physicist named Peter 
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Mansfield. In 2003 they jointly were awarded the Nobel Prize for physiology or 
medicine. 
Although scientifically accurate, in clinical practice the N was dropped from the 
acronym NMR due to its negative associations with nuclear energy and weapons, and 
MRI became the preferred term for diagnostic imaging using NMR. In the decades 
that have passed since it was first described, MRI has become the most important tool 
for in vivo investigations of brain structures and function in neurological diseases. It 
has also increased our knowledge about normal brain function and development. 
 
1.2.2 MRI principles 
The MRI system consists of a superconductive stationary magnet providing the main 
magnetic field, and it is in this large magnet the patient is placed when scanned. The 
powerful magnet is located in a shielded RF room protecting it from external, 
unwanted RF radiation. An internal RF system consisting of coils generates 
excitatory RF pulses used to excite nuclei in the body (transmitter coils) or to detect 
signals emitted from the NMR process (receiver coils). Strength and spatial location 
of the emitted signals and the various imaging techniques are made possible through 
a gradient system, which is also part of the MRI system. Finally, computers detect 
and transform the magnetic resonance signals into what we now know as MRI. In the 
following section, I will try to provide a basic explanation of the complicated process 
behind this fantastic tool. 
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The main principle behind MRI is based on absorption and emission of energy in the 
hydrogen nuclei in the body caused by RF pulses. The hydrogen nucleus contains 
only one proton, and it is therefore also often referred to as a proton. The majority of 
clinical use of NMR today is based on the hydrogen nuclei. This is due to hydrogen 
nuclei providing the best magnetic resonance signals, and that they are very 
numerous in humans as part of the water molecules in our body.83 Protons have a 
single positive charge, and they all spin around their own axes. In this way, each 
proton generates a tiny magnetic field known as a magnetic moment. The many small 
spinning magnetic moments in our body will try, similar to a bar magnet, to align 
themselves with the main magnetic field of the MRI scanner. As a result of this, each 
proton will spin with a frequency (named the Larmor frequency, given by the strength 
of the magnetic field) either parallel (the lowest energy state) or anti-parallel to the 
main field. For every million of anti-parallel protons, there are a-million-and-four 
parallel protons. In MRI one utilizes the net parallel magnetization moment of all the 
protons to obtain information about the tissue of interest.82  
 
In order to measure this magnetic moment, protons need to be exposed to RF pulse 
stimulation. A 90˚ RF pulse with Larmor frequency will create resonance resulting in 
protons being flipped out of their axes in the z-plane of the main magnetic field and 
down in the x-y transverse plane. The MRI system is created so that we can detect the 
magnetic moments as vectors in this transverse plane. Within seconds protons will 
return to their former equilibrium position in the z-plane and in this process they will 
lose energy detectable as a NMR signal.82 
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The loss of energy (i.e. relaxation) consists of two parallel processes: 1) a dephasing 
of spins in the x-y plane called the spin-spin relaxation and 2) realignment of protons 
along the z-axis. In various body tissues, the relaxation process is different based on 
their molecular structure and their number of protons, and this can be used to 
differentiate amongst them and provide image tissue contrasts. 
 
1.2.3 Tissue contrast in MRI 
1.2.3.1 T1 contrast 
As described above, the executing RF pulse will add energy to the protons and flip 
them away from the z-axis producing a NMR signal. With time, the protons will 
return to their former low energy state, the NMR signal will gradually decay and 
disappear. The time it takes for the added energy to diminish, and the protons again to 
align with the external main magnetic field, is different in various tissues. By 
definition, the T1 relaxation time is the time it takes for 63 % of the protons to be 
realigned along the z-axis. Protons’ ability to lose energy to the surrounding 
environment molecules (the lattice) is referred to as the T1 relaxation property of the 
tissue, also called spin-lattice relaxation. The T1 relaxation properties depend on the 
motional frequencies of the molecules contributing to the lattice. In tissue, where this 
motion is at the Larmor frequency, the T1 relaxation is more efficient and the T1 
relaxation time is shorter. A short T1 relaxation time is typically seen when the 
protons are intermediately bound to their surroundings, e.g. fat, and this is seen as a 
very bright signal. In both free fluids and in solids, the spin-lattice relaxation is 
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reduced and the T1 relaxation time is longer (represented with a darker signal). In a 
T1 weighted MRI scan of the brain, gray matter will appear with intermediate gray 
signal, white matter will have a lighter white signal and cerebrospinal fluid (CSF) 
appears dark.82 (Figure 1.2) 
 
 
Sagittal T1 weighted brain MRI scan. 
Figure 1.2  
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1.2.3.2 T2 contrast 
The T2 relaxation time is defined as the time it takes until the NMR signal in the 
transverse x-y plane is reduced to 37 % of its value immediately after the executing 
90˚ RF pulse.83 The flipped protons will continue to produce an NMR signal in the 
transverse plane as long as they remain in coherent spinning. T2 decay describes the 
process when the protons change phase, become dephased and lose their transverse 
magnetization.82 T2 decay is also different in various tissues, depending on its degree 
of natural motional frequency, and the T2 relaxation is therefore also named spin-spin 
relaxation. In tissue consisting of large protons, the T2 relaxation is faster because the 
flipped protons have reduced capacity to move freely due to large local magnetic 
field variations. This is seen in solid tissue or in fluids containing proteins, where the 
transverse relaxation happens fast, the NMR signal decays in a short period of time 
and the MRI signal appears in shades of gray or dark. In pure water, the protons can 
move freely around and remain in phase for a long time, resulting in a strong NMR 
signals. In T2 weighted brain MRI scans, the gray matter will appear light gray, the 
white matter will have a darker gray signal and cerebrospinal fluid will appear very 
bright. (Figure 1.3) 
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1.2.4 Volumetric MRI 
Volumetric MRI acquisitions are made available through technical advances in recent 
years. In three-dimensional (3D) MRI of the entire volume of interest (e.g. the brain) 
is divided into very thin contiguous slices resulting in numerous cubes, called voxels. 
Voxel sizes as low as 1x1x1 millimetres are possible. This is considered an advantage 
as it reduces partial volume effects, but there is a trade-off since it may reduce signal-
to-noise ratio. 3D MRI sequences are time consuming and can be more susceptible to 
artefacts, but are increasingly used also in clinical practise because of the high 
resolution and great potential of image reformations provided by the raw data.82 
 
Axial T2 weighted brain MRI scan.  
Figure 1.3 
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1.2.4.1 Volume analyses of structural brain MRI. 
In contrast to traditional pathoanatomical methods, morphometric MRI allows in-vivo 
investigations of the brain, and the field of MRI-based brain morphometry has 
developed extensively during the last years.84  
 
Previously, and still in most clinical settings, structural brain MRI are analysed 
qualitatively by investigators reading scans based on their experience and expertise. 
This lack of objectivity causes problems in research settings when aiming to compare 
with other work in the field. As a result, many semi-quantitative scales have been 
developed. An example is the Fazekas’ scale for estimation of ischemic white matter 
pathology.85 With technical developments providing increasing amounts of MRI data 
(e.g. in research settings) and a need for more accurate and objective analyses, a 
number of quantitative analysing methods have been developed. 
 
Quantitative volumetric brain MRI analyses can estimate unspecific global scale 
characteristics, e.g. whole brain volume, or more tissue-specific volumes like total 
gray matter, total white matter or total CSF volumes. This approach has the 
advantage of being relatively robust and fast, but offers less detailed information. 
Another approach is the estimation of local volumetric changes. The advantages of 
obtaining data on regional changes must often be weighted against a more time-
consuming and less robust method. In order to obtain regional quantitative volume 
data from the brain, manual tracing has been used extensively, e.g. in hippocampal 
analyses.86 Manual tracing is very time consuming as it implies that one has to draw 
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around anatomical structures on each slice throughout the whole volume. 
Development of automatic and time saving computerized methods is therefore an 
active research area, and several such software packages are now available, e.g. 
FreeSurfer (http://surfer.nmr.mgh.harvard.edu/).  
 
Manual hippocampal tracing analyses are examples of a region of interest (ROI) 
approach, where specific brain regions are investigated based on hypothesis on where 
to expect the pathology. Lately, unbiased computerized methods have been developed 
where the whole brain is analysed for local pathology detected by statistical 
evaluation of all the brain voxels, e.g. Statistical Parametric Mapping (SPM) 
(http://www.fil.ion.ucl.ac.uk/spm) 
 
1.2.4.2 General principles of computerized brain volume analyses 
Several different approaches exist for estimation of volumetric brain parameters from 
3D MRI volume acquisitions, but the various methods have some fundamental 
concepts and techniques in common. These include magnetic field bias corrections, 
registration of brains into a reference space and segmentation of brain tissue classes 
and/or anatomical structures. The many computerized methods available have solved 
these issues in different ways, and their performances are under continuous 
investigation. Comparative studies have been published, but the internal validity of 
the methods has been difficult to establish due to the lack of a gold standard. Most 
previous validation studies used manual ROI segmentations as source reference. 
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Recently, developments of realistically simulated data, have been a great 
improvement in this field of research.87   
 
The choice of method for MRI analysis depends on several factors: the experience 
and competence of the operator, the computer resources available and, finally, the 
quality of the MRI data and robustness’ of the algorithms highly influence the 
success rate of computer-based methods. 
 
1.2.5 White matter hyperintensities analyses 
White matter hyperintensities (WMH) are bright signal changes in the white matter 
seen in T2 weighted images. They are typically seen around the ventricles 
(periventricular WMH), but also as focal lesions in the deep white matter. WMH are 
best appreciated on MRI fluid attenuated inversion recovery (FLAIR) sequences. 
FLAIR is a special T2 weighted sequence where the high signal of ventricular fluid is 
suppressed resulting in a better contrast between periventricular WMH and 
intraventricular CSF. (Figure 1.4) 
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Earlier work estimated the amount of WMH from T2 weighted MRI scans using 
various visual qualitative rating scales.
85,88,89
 These scales are easy to implement and 
relative insensitive to artefacts, but have limitations regarding objectivity and ceiling 
effects.
90
 Recently, computerized volumetric analyses have become more widely 
used, both fully automatic and semi-quantitative methods.  Comparison of the 
different methods has shown that visual scoring is less sensitive than volumetric 
assessment,
90
 and that automated quantitative segmentation methods are suitable for 
assessing impact on cognitive function.
91
 Others have found that visual rating is as 
good as the more complex methods in routine clinical practice, but that volumetric 
assessment should be used in research settings. 
92
  
 
 
Axial FLAIR brain MRI pulse sequence.  
Figure 1.4 
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1.2.6 MRI and the aging brain  
In the past couple of decades, published papers using MRI in the characterization of 
neurodegenerative diseases are numerous. The pathology coexists with normal age-
related processes, and it is therefore important to understand normal brain MRI 
changes during aging.  
 
1.2.6.1 Whole brain, gray and white matter volumes 
Many studies have investigated how normal age changes relate to MRI depicted brain 
tissue volumes.93-96 A large study of more than 2200 participants (age range 34 to 97 
years) found that age explained about 50 % of differences in total brain volume.94 
Frontal lobe volumes showed the greatest decline with age. Age-related changes were 
in general small before the age of 50 years. Another study (370 adults age 18 to 97) 
also showed an age-related decrease in total brain volume, starting from age 30, with 
later onset of white matter than gray matter loss.96 Recently, studies have shown 
consistent and widespread neuroanatomical age-related subcortical97 and cortical98 
volume differences when analyzing multiple samples using the same method.  
 
Investigating the relationship between changes in hippocampal and cortical gray 
matter volumes and cognitive functions in healthy elderly, Kramer et al. found in 
their longitudinal study that reduced volume of hippocampus was associated with 
decline in episodic memory function and that reduction in cortical gray matter 
volumes were associated with executive dysfunction.95  
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Results on the impact of gender on longitudinal brain tissue volumes are conflicting. 
Studies have found no impact of sex after controlling for larger skull size in 
men.94,96,99 Others show increased gray matter loss in men.93 Results from a large 
multisample study concluded that sex had negligible effects on aging in both healthy 
subjects and in patients with AD.100 
 
1.2.6.2 White matter hyperintensities 
WMH occur with increased frequencies with higher age in healthy subjects. A 
population based study showed that, of 1077 subjects between 60-90 years of age, 
only 5 % had no WMH detectable on MRI.101 Most studies show that women have 
more WMH changes than men,101 but there are others reporting that there is no such 
difference.102 WMH are also characteristic findings in conditions associated with 
cerebrovascular risk factors, e.g. vascular dementia,103 and in inflammatory brain 
disease like multiple sclerosis.104 Bright signal white matter lesions on T2 weighted 
MRI are thus unspecific MRI findings, and the histopatholological findings of WMH 
are different depending on the underlying condition. An early report on incidental 
WMH showed that punctuate deep and irregular periventricular WMH corresponded 
to ischemic tissue damage, while smooth periventricular rims of WMH were of non-
ischemic origin with demyelination, subependymal gliosis and discontinuities of the 
ependymal lining.105 This was questioned in a recent neuropathological paper 
showing that all age-associated WMH are results of brain vascular damage.106  
Restricted cerebral perfusion in areas with WMH is depicted below in Figure 1.5 
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Cerebral computer tomography (CT) angiography (left) showing extensive 
periventricular hypoattenuation (findings corresponding to MRI T2 white 
matter hyperintensities) and perfusion CT blood flow analyses (ml/100 ml/min) 
(right) illustrating restricted blood flow in areas of periventricular white matter 
pathology.  
Courtesy of Dr. Mona K. Beyer, Dep. of Radiology, Stavanger University 
Hospital. 
 
 
Figure 1.5 
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The previously cited study by Kramer and colleagues found that WMH changes in 
healthy elderly brains also were associated with reduced executive functioning.95 A 
recent study showed that age-associated periventricular WMH in non-demented 
subjects were associated with reduced cortical cholinergic receptor activity.107 This 
suggests that disruption of cholinergic projection fibres in periventricular white 
matter could serve as a substrate for the cognitive deficits associated with WMH. 
Despite the findings of age-related WMH influencing cognitive status, some studies 
report that there is no such relationship. These suggest that MRI might be 
oversensitive when it comes to WMH, and that higher water content in the brain does 
not necessarily result in loss of function.108 The association between WMH 
(especially low grade) and cognition in non-demented individuals is at the present 
time complex and not fully understood.  
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1.3 Structural MRI findings in PD 
The next section, discussing structural MRI in patients with PD, will be restricted to 
previous volumetric studies that included non-demented and demented patients in 
addition to patients with MCI. 
 
As patients included in this thesis are all newly diagnosed, focus will be given to 
studies of patients in early disease stages. The term early disease stage may, as in this 
present work, be used as a description of newly diagnosed patients with relatively 
short disease duration irrespective of disease severity. But the term can be 
problematic since early PD is also used to describe non-advanced PD not accounting 
for disease duration.  In the following, we have tried to separate between non-
advanced disease as in the meaning of limited clinical disease and early disease 
meaning restricted disease duration.  
 
1.3.1 Morphological analyses of brain MRI in non-demented patients with PD 
Few previous studies have investigated changes in whole brain volumes in early PD, 
and these studies (including 27 and 16 patients) did not find any evidence of 
significant whole brain atrophy in their patients with PD.109,110  In small sample 
studies of patients with longer disease duration, similar conclusions were drawn.110-113 
In order to obtain more confident results, the degree of whole brain atrophy in PD 
needs to be investigated further including larger samples of patients.  
The majority of regional structural MRI studies in newly diagnosed PD have been 
ROI based and focused on the substantia nigra degeneration and its value as a 
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diagnostic tool. Regarding early non-demented patients with PD, only a couple of 
studies have addressed regional brain atrophy. Geng et al.110 reported reduced 
putaminal volume in patients (n=16) with limited disease severity and disease 
duration of about two years when compared to controls, and even more reduction in 
advanced stage patients with a mean disease duration of about five years (n=8). The 
volume of putamen was correlated with disease severity. This study also found 
pallidal atrophy in advanced disease, but there was no significant volume loss in 
substantia nigra or nucleus caudatus in any disease stage. Bruck and collegues114 
found hippocampal and prefrontal lobe atrophy in 22 unmedicated non-demented 
patients with PD (mean disease duration 1.7 years), and that impaired memory was 
related to hippocampal atrophy and reduced sustained attention to prefrontal tissue 
loss.  
 
A manual ROI approach was also used to achieve a better in vivo understanding of 
the brain changes in non-demented patients with longer disease duration. Alegret et 
al.115 found that ventricular (third and lateral) enlargement in rather advanced patients 
with mean disease duration of about 14 years was correlated with memory and frontal 
lobe functions, and that reduced putaminal volume was associated with poorer motor 
functions.  
 
 
Many previous ROI studies have focused on the medial temporal lobes and the 
majority in patients with relatively long disease duration. The reason for this is that 
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degenerative changes in the hippocampus are established as pathologic hallmarks of 
AD and there is a need to develop imaging tools that can differentiate between the 
various neurodegenerative diseases. The first such study described in 1996 
hippocampal atrophy in both non-demented and demented patients with PD. The 
degree of atrophy was less than in AD, but more than in a group of patients with 
vascular dementia.116 Hippocampal atrophy was also found in a later study in patients 
with PD, although to a lesser degree than in patients with PDD suggesting a 
progressive pattern.117 Bouchard and colleagues detected age related hippocampal 
atrophy in patients with PD, both non-demented and demented subjects.118 Still, all 
these findings are in contrast to a study reporting that hippocampal atrophy in non-
demented patients with PD was not statistically significant.119  
 
In the past few years, several operator independent VBM studies have investigated 
various aspects of PD, but again few studies exist that include patients with short 
disease duration. Nagano-Saito reported no differences in gray matter densities 
comparing cognitively intact patients with PD and normal controls. Only when 
analysing a subgroup of rather advanced stage patients (mean disease duration 
4.9±4.3 years,Hoehn & Yahr (H&Y) stage >2), atrophy was found in bilateral 
orbitofrontal cortex, left ventrolateral cortex and left parahippocampal gyrus.120 
Recently, Ibarretxe-Bilbao et al. found significant gray matter loss in the right 
amygdale and bilateral orbitofronal cortex in a VBM study of early stage non-
demented patients with PD (disease duration 3.1±1.6 years and H&Y 1.7±0.4) 
 60 
compared to controls. The atrophy in orbitofronal cortex was associated with 
impaired recognition of emotions and decision-making impairment in PD.121 
 
The studies of patients with longer disease duration show conflicting results, and 
VBM studies have failed in detecting consistent significant regional brain atrophy in 
non-demented PD. Burton et al.122 showed reduced gray matter volume in the frontal 
lobe of 31 patients with PD (disease duration about 44 months, mean age 75 years 
and mean Unified Parkinson’s Disease Rating Scale (UPDRS) III 26), while Beyer et 
al.123 found reduced gray matter in the superior temporal region in a group of 20 
patients with PD (disease duration 12 years, mean age about 73 years and mean H&Y 
2.4). Other studies report atrophy in nucleus caudatus and associated ventricular 
enlargement,124 hippocampus and anterior cingulate,125 intra-parietal sulcus,126 
superior temporal and frontal gyrus127 and cerebellum.128 
 
Most previous volumetric studies have focused on possible presence of gray matter 
atrophy in patients with PD. A recent study might represent a somewhat change of 
focus in VBM studies. In this study comparisons of 26 early, untreated patients with 
PD and 14 healthy controls revealed no significance in local gray matter volumes. In 
PD, however, there was reduced white matter volume in the right temporal lobe.129 
The clinical significance of this finding is at present time unknown especially since 
there were no correlations between the local white matter volumes and 
neuropsychological tests reflecting memory and visuospatial processing. 
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Another newly published VBM study also reported white matter atrophy in addition 
to lack of gray matter loss in patients with PD.130 Interestingly, the atrophy cluster 
was located in the brainstem and thus somewhat in accordance with the Braak 
hypotheses.32 In this study the included patients had limited disease severity (H&Y 
stage I and II), but had a rather long disease duration (mean duration since first 
diagnosis about 6 years). These preliminary results are very interesting, but need to 
be validated in future, larger studies. 
 
In summary, studies investigating volumetric changes in the brains of patients with 
newly diagnosed PD are few and inconsistent. Furthermore, results from studies of 
more advanced stage patients with PD and of patients with longer disease duration 
without cognitive impairment, are not conclusive. It must be noted that the above-
mentioned structural MRI studies are limited by many factors. In early disease the 
diagnosis of PD might be difficult and patients with other parkinsonian disorders 
could possibly have been included. Secondly, all studies included few patients which 
might mask significant results given the known heterogeneity in PD. Finally, lack of 
consistency in MRI protocols and analyses makes it difficult to compare the various 
studies in order to draw general conclusions.  
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1.3.2 MRI brain atrophy in patients with PDD 
Results from previous structural MRI studies on patients with PD and dementia are 
restricted by many of the same limitations as outlined above, but in general, more 
consistent significant brain MRI changes have been found than in non-demented 
patients. Manual ROI studies have detected atrophy of hippocampus,116-119 
amygdala,118,119 and enthorhinal cortex.131 VBM studies have also reported strong 
(results corrected for multiple comparisons) findings of atrophy in patients with PDD 
compared with controls in hippocampus132  and right cuneus in addition to left 
inferior parietal region.133 Other studies report widespread atrophy using less 
stringent statistical tresholds.122,123,125 Despite all efforts, a specific pattern of gray 
matter atrophy in PDD is yet to be established.  
 
A recent VBM study reported findings from hippocampal volume analyses in patients 
with advanced PD, including PDD and non-demented patients with and without 
visual hallusinations.132 Ibarrextxe-Bilbao and colleagues here found that the PDD 
group had hippocampal gray matter reductions in the entire hippocampus, while non-
demented patients with visual hallucinations showed significant reductions only in 
the hippocampal head. Non-demented patients without visual hallucinations did not 
have any gray matter tissue loss. 
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1.3.3 MRI brain atrophy in patients with PD and MCI 
Along with the growing interest of establishing possible characteristics of a pre- 
dementia stage in PD, a few recent structural MRI studies have looked for brain 
changes in patients with PD and MCI. The first two studies in the field were both 
published in 2007. Meyer et.al134 reported using ROI methods and visual rating, that 
parkinsonian patients (including both PD and DLB) with MCI was characterized by 
third ventricular enlargement, but also a certain degree of atrophy in the entorhinal 
cortex when compared to MCI subjects who later converted to AD. When compared 
to normal controls, parkinsonian patients with MCI also showed frontal and temporal 
lobe and hippocampal atrophy in addition to frontal horn ventricular enlargement. In 
this study parkinsonian patients with MCI did not differ from parkinsonian patients 
with dementia for any MRI variable.  
 
Beyer and colleagues123  showed in a VBM study gray matter atrophy in left frontal 
and both temporal lobes comparing patients with MCI with patients with normal 
cognition, but results were not corrected for multiple comparisons and were no longer 
present when age and gender was included as covariates in analyses. Both previous 
studies included old patients with advanced disease. Patients were few, and the 
studies differed in methods regarding PD diagnosis, neuropsychological assessment 
and MRI analyses and results must therefore be interpreted with caution.   
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1.3.4 Longitudinal volumetric MRI studies in PD 
Longitudinal studies of whole brain volume loss in PD are conflicting. A two year 
follow-up study using semiautomatic methods indicated significant percentage whole 
brain loss in 8 non-demented PD patients (-0.81 % /year) compared to 10 controls (-
0.04 %/year).135 Increase in ventricular size was not significantly different between 
groups, and visual inspection showed diffuse gyral atrophy in the temporal, parietal 
and frontal cortex in patients with PD. Brain volume loss was correlated with 
measurements of global cognitive functions and symptom duration. Later, Burton et 
al. found rates of brain atrophy over one year no different between 18 patients with 
PD (0.31±0.69 %/year) and 24 age–matched controls (0.34±0.76 %/year). 
Interestingly, this latter study found brain atrophy rates significantly increased in 13 
patients with PDD (1.12±0.98 %/year), but there were no significant correlations 
between increased atrophy rates and age or dementia severity.136 
 
A longitudinal VBM study detected gray matter loss in 8 advanced stage patients 
with PD without dementia over a period of about two years in limbic, paralimbic and 
temporo-occipital regions. Eleven patients with PDD showed decrement in mainly 
the neocortex.137 Later, another VBM study found no evidence of gray matter atrophy 
in PD patients after a follow-up of about 1.4 years.138 Finally, a recent VBM study 
found increased (over a period of about 29 months) brain atrophy and conversion to 
PDD in patients with PD and visual hallucinations compared to patients with no such 
hallucinations.139 
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For the PDD group, longitudinal MRI has been suggested as a marker for disease 
progression and possibly for detection of effects of disease-modifying treatment in 
clinical trials,80 but further studies investigating longitudinal evolution of brain 
atrophy in PD are clearly needed. A better understanding of the natural course of the 
pathological processes is necessary in addition to an improved understanding of the 
various patient subgroups in which different rates of atrophy may predict various 
clinical phenotypes.  
 
1.3.5 MRI WMH studies in PD 
The influence of WMH in PD is at present not established. The majority of previous 
studies have used various semi-quantitative rating scales, and most studies have 
investigated possible correlations between WMH and disease severity. Lately, studies 
have also focused on the relationship between WMH and cognitive dysfunction. The 
pathophysiological explanation for clinical influence of WMH is not completely 
understood, but disruption of white matter fibre tracts has been suggested. A possible 
link between WMH and gait disability could be due to interrupted cortical-subcortical 
tracts involved in gait and balance.140 The same mechanism has been proposed for 
periventricular WMH affecting cognition by disconnecting major cholinergic 
tracts.107  
 
In 1995 Piccini and colleagues published a study showing, by use of semi-
quantitative rating, that 102 non-demented patients with PD had more periventricular 
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WMH than controls, and that the patients with periventricular WMH had more 
advanced disease at shorter duration of symptoms than patients without 
periventricular WMH.141 An association between disease severity and WMH was also 
the conclusion of a recent study including 141 patients with PD; Lee at al. found that 
WMH was correlated especially with axial symptoms and independently associated 
with the postural instability and gait difficulty motor subtype of PD.140 Still, these 
studies are contrasted by work reporting that WMH were not significantly related to 
PD motor symptoms.142 
 
Regarding the influence of WMH on cognitive functions in patients with PD, 
previous studies have also shown conflicting results. A couple of newly published 
studies found that vascular risk factors and WMH changes did not contribute to 
cognitive impairments in PD.25,143 Earlier work by Beyer et al.144 found that demented 
patients with PD had higher total WMH deep, periventricular and frontal deep WMH 
load than non-demented patients and concluded that vascular factors thus might 
influence cognitive status in advanced PD. It must be noted that the total PD group 
was not different from controls with respect to WMH. In this study deep WMH were 
significantly associated with the MMSE145 performance. Another study also 
suggested vascular pathology as possible explanation for PDD and showed that 
subjects with parkinsonian dementia had higher mean severity of WMH compared to 
NC.146 Still, these latter cross-sectional findings are not supported by the only 
longitudinal study in the field. Burton et al.147 showed, as the only study utilizing 
automated volume quantification, higher baseline mean total WMH volume in AD, 
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but not in PD with dementia or DLB compared to normal controls. WMH progression 
over one year was no different between groups, and change in WMH volume did not 
correspond to change in global cognitive performance.  
 
With respect to previous work on the impact of WMH on MCI in PD, Meyer et al. 
reported that in their small sample of parkinsonian MCI patients did not differ from 
controls or demented parkinsonian patients with respect to vascular brain lesions.134 
Recently, Rodriguez- Oroz and collegues25 published a cross-sectional study showing 
no difference in WMH burden in patients with advanced PD, irrespectively of 
cognitive  group status; cognitively normal, having MCI or suffering from dementia. 
 
WMH are possible preventable contributing factors to cognitive dysfunction in 
patients with PD. Given the limited number of previous studies in this important 
field, it is evident that more studies are needed. 
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2. Hypotheses  
 
The aim of this thesis was to test the hypothesis that cognitive impairment in newly 
diagnosed PD is related to brain atrophy and/or WMH changes in the brain. By 
studying a large number of unselected patients with incident PD from a community-
based study we wanted to search for a possible neurobiological basis for their 
cognitive deficits. To achieve this, we applied various widely used and previously 
validated structural MRI methods providing us with different levels of information.   
 
Paper I 
In other neurodegenerative diseases with dementia, especially AD, whole brain 
atrophy is a surrogate marker for cerebral pathology even in early disease stages.148 
Furthermore, age-related vascular changes in the brain represented as WMH, are also 
associated with cognitive dysfunction.149 Based on this, we hypothesized that global 
loss of brain tissue and/or high WMH load is present and may be contributing factors 
to the cognitive deficits observed in a large unselected cohort of patients with early 
PD. 
 
Paper II 
Previous VBM studies have found regional gray matter atrophy in advanced PD, in 
PD with dementia and PD with MCI.122,123 We therefore hypothesized that MCI and 
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reduced cognitive performance in patients with early PD also would be associated 
with VBM detectable focal gray matter loss. 
  
Paper III 
In a sample of patients with advanced PD, our group previously found that frontal 
deep, periventricular and total deep WMH were increased in advanced stage 
demented patients with PD compared to non-demented patients, although the whole 
PD cohort did not differ from controls with respect to total WMH.144 WMH might be 
especially associated with frontal lobe domains including executive function, 
attention and processing speed and working memory.149-151 To further explore the 
cognitive impact of WMH in patients with PD, we tested the hypothesis that WMH, 
total volume and according to regional distribution, contribute to MCI and the 
attention/executive cognitive dysfunctions in patients with newly diagnosed PD. 
 
Paper IV 
The Braak hypothesis suggests that PD pathology in very early clinical stages should 
be mainly concentrated in brainstem nuclei, forebrain and to some extent the 
temporal mesocortex.152 Neuropathological work has found that brainstem pathology 
is associated with dementia in patients with PD.153 In this paper we tested the 
hypothesis that MCI in newly diagnosed PD is associated with subcortical brain 
tissue loss detectable on structural MRI. 
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3. Methods 
 
3.1 Subjects 
 
All subjects included in this thesis are part of the Norwegian ParkWest study.10 This 
is a population-based multi-center prospective longitudinal cohort study of patients 
with incident PD from Western and Southern Norway. The study comprises patients, 
their caregivers and a control group with similar age and sex distribution. This sample 
is to be followed prospectively for 10 years.  
 
3.1.1 Patients 
A total of 265 patients met the diagnostic criteria of PD, and 212 consented to 
participate in the 10-year longitudinal ParkWest study (diagnostic procedure as 
outlined below in section 3.2). As discussed in section 1.3, we have defined our 
patients as patients with early stage PD in the sense that they are newly diagnosed, 
irrespectively of their degree of clinical disease expression.  
 
3.1.2 Controls 
In the Norwegian ParkWest study an age-and sex matched control group was also 
recruited. The controls consisted of subjects in the following preference order: 
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patient’s spouse, a friend in the same age-group as the patient, or unrelated persons 
from social clubs for the elderly in the study area. Exclusion criteria for controls were 
dementia, parkinsonian symptoms at clinical examination and previous or current 
treatment with anti-parkinsonian medication. In addition, the controls should be able 
to carry out the baseline and planned examination programme. 
 
3.1.3 MRI cohort 
An MRI examination was performed as part of the baseline assessment in 182 
patients with PD, and in 109 of 205 controls at four centres: Stavanger (45 patients 
and 42 controls), Haugesund (11 patients and 2 controls), Bergen (106 patients and 
37 controls), and Arendal (20 patients and 28 controls).  
 
The number of scanned controls in Bergen, was limited due to economical 
restrictions. With respect to patients lacking a representative MRI scan, the reasons 
for this were wrong or incomplete protocol (n=8), claustrophobia (n=6), poor health 
incompatible with MRI (n=4), MRI contraindications e.g. pacemaker (n=5) or they 
refused to be scanned (n=2). For unknown reasons, five patients with PD did not have 
a MRI scan. 
 
Mean time interval between baseline clinical and neuropsychological evaluation and 
MRI scan was 32 (standard deviation ± 44) days in the patient group and 174 
(standard deviation ± 144) days for controls. 
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Before all image analyses, we excluded subjects with gross brain pathology known to 
influence segmentation outputs, e.g. large cortical infarcts (n=4) or arachnoid cyst 
(n=1). We also excluded subjects with major scan artefacts. Due to the use of 
different MRI series in the various analyses, this varied among the different studies 
using 3D T1 weighted series (Paper I, II and IV) and FLAIR (Paper I, II and III). 
Furthermore, the final number of subjects included in each study depended on 
requirements and performance of the imaging analysis tools. Detailed descriptions of 
the final study sample for the various studies can be found in each separate paper.  
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3.2 Diagnostic procedure of PD 
 
In the Norwegian ParkWest study a comprehensive case ascertainment system, using 
all available resources both in hospital-based and community-based health care, 
resulted in a population-representative cohort of all residents in the study area who 
were diagnosed with incident PD between November 1st, 2004, and August 31st, 
2006. All patients were diagnosed with PD according to research criteria as described 
in section 1.1.8 28 The final diagnosis was made, in a four-step procedure after an 
average follow-up of 28 months, through an independent evaluation and final 
consensus by two senior movement disorder specialists. In making the diagnosis, the 
study neurologists took all available patient material; medical history, clinical 
examination, imaging data and a possible response to dopaminergic treatment into 
consideration. None of the included patients had a history of marked cognitive 
decline before signs of motor symptoms or within the first year of the disease. 
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3.3 Clinical assessment tools 
 
In all subjects we recorded the demographic variables age, gender and years of 
education. Additional clinical and neurological assessments were carried out as 
described below.  
 
3.3.1 Assessment of parkinsonism and disability 
For the papers in this thesis, we rated the severity and stage of PD using the 
UPDRS154 and the H&Y scale.155  
 
The UPDRS154 was developed in 1987 and evaluates four components of PD: 
mentation, behaviour and mood (part I), activities of daily living (part II), severity of 
motor symptoms (part III) and therapy complications (part IV). Of these, we used the 
subscore III as an assessment of severity of parkinsonism in our patients with PD.  
 
The H&Y scale155 was published in 1967 as a tool to evaluate disease progression, 
measured by impairment and disability of movements, balance and gait. The scale 
ranges from 0 (no motor symptoms) to 5 (bilateral parkinsonism and not able to 
walk). 
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3.3.2 Assessment of depression 
We estimated severity of depressive symptoms using the Montgomery-Aasberg Scale 
(MADRS).156 The MADRS was recently validated in patients with PD.157 
 
3.3.3 Assessment of cognitive impairment 
In the Norwegian ParkWest study, global cognitive status was screened with the 
MMSE.145 
 
A diagnosis of dementia associated with PD was made according to proposed 
consensus criteria.44 The diagnosis was based on neuropsychological testing, clinical 
history from a standardized caregiver questionnaire (the IQCode),158 in addition to the 
clinical examination. 
 
Assessment of possible cognitive changes in patients with early PD was done using 
neuropsychological tests exploring cognitive domains that we know are affected in 
PD. The neuropsychological battery was chosen with tests that were not or only 
minimally affected by motor performance: 
 
The California Verbal Learning test II (CVLT-II)159 evaluated verbal memory. 
CVLT-II consists of 16 words which were read five times, and after each time the test 
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subject is asked to recall as many words as possible. We included total immediate 
recall (sum of trials 1-5), short-delay and long-delay free recall (after 20 minutes) 
scores in our analyses. 
The Silhouettes subtest from the Visual Object and Space Perception Battery 
(VOSP)160 tests visuospatial abilities. In this test, the subject is asked to identify the 
outline of 30 objects, which are rotated through varying degrees from the lateral axis. 
 
The Semantic verbal fluency tests how many names of animals the subject can 
generate in 60 seconds. 
  
The Stroop test161 is a test of selective attention and executive functions. In the 
interference part of the Stroop test, the test subject is asked to name the color of the 
word (which is printed in colored ink different from the printed name, 3rd card). 
Psychomotor speed was examined using the sum of words produced during the color 
(colored patches, 1st card) and the word (printed words, 2nd card) conditions. 
 
The Serial 7 test from the MMSE145 was also used to assess attention and executive 
functions. In this test the subject is asked to subtract serial 7’s from 100.  
 
Based on these tests, three cognitive domains were calculated: a) memory (CVLT-II), 
b) attention and executive functions (Serial 7 from MMSE, Semantic verbal fluency, 
Stroop words, colors and color-words) and c) visuospatial functioning (VOSP 
silhouettes). Since age, sex and education affect performance on cognitive tests, 
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multiple regression analyses were performed using data from the healthy control 
subjects for each of the cognitive domains. The resulting regression formulae were 
used to calculate expected z-scores for the patients with PD based on age, sex and 
education.  
 
3.3.4 MCI classification 
MCI was classified based on performance in the three cognitive domains. Using a 
modified version of the criteria for MCI,59 subjects without dementia, but with an 
observed age-and education corrected z-score deviating more than -1.5 standard 
deviations from the expected z-score in at least one cognitive domain, were classified 
as having MCI. We refer to Aarsland et al. for further details.64 
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3.4 MRI and image analyses 
 
Quantitative image analyses were performed at the Buffalo Neuroimaging Analysis 
Center (BNAC), Buffalo, NY, USA during the period from June 2007 to June 2008. 
Operators blinded to clinical characteristics and tests results performed the MRI 
analyses. As principal investigator on all the papers included in this thesis, T.O 
Dalaker was involved in all MRI analyses, although with excellent help from 
knowledgeable co-authors at the BNAC. 
 
3.4.1 MRI imaging protocol 
The MRI scans were performed at four imaging centres using a common protocol. A 
1.5 T scanner was used in three centres (Philips Intera in Stavanger and Haugesund 
and Siemens Symphony in Bergen) and a 1.0 T Philips Intera system was used in 
Arendal. The protocol included a coronal 3D T1 weighted sequence used for brain 
volume calculations, and an axial FLAIR sequence used for classification of WMH. 
Sequence parameters for each MRI site were as follows: 
 
For the 3D T1 weighted sequence: Stavanger: repetition time [TR]/echo time [TE] 
10.0/4.6 msec, flip angle 30.0 degrees, 2 mm slice thickness with 1 mm spacing 
between slices (1 mm slices with no gap), Number of excitations [NEX] 2, Matrix 
256x256; Haugesund: TR/TE 20.0/4.6, flip angle 30.0, 1 mm slice thickness with 1 
mm spacing, NEX 1, Matrix 256x256; Bergen: TR/TE 2130.0/3.9, flip angle 15, 1 
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mm slice thickness/ no gap, NEX 1, Matrix 256x256, Arendal TR/TE 25/6.9, flip 
angle 30.0, slice thickness 2 mm with 1 mm spacing, NEX 1, Matrix 256x256.  
 
For the FLAIR sequence: Stavanger: TR/TE 6000/100, inversion time [TI] 2000, 4 
mm slice thickness/1 mm gap, NEX 2, Matrix 256x256, Haugesund: TR/TE/TI 
6000/110/2000, 4 mm slice thickness/1 mm gap, NEX 2, Matrix 256x256, Bergen: 
TR/TE/TI 8400/103/2500, 4mm slice thickness/0.4 mm gap, NEX 2, Matrix 
256x204, Arendal: TR/TE/TI 6000/100/1900, 4 mm slice thickness/1 mm gap, NEX 
2, Matrix 256x256.  
 
3.4.2 WMH analyses 
WMH were outlined on each axial FLAIR image slice using a reproducible, semi-
automated local thresholding technique with Java Image Manipulation software 
(version 4.0, Xinapse Systems, Northants, UK, http://www.xinapse.com). All WMH 
were contoured by a single rater (TOD) with similar reproducibility, as previously 
reported.162 Reproducibility of the technique was calculated as a coefficient of 
variation (100 % x standard deviation/mean). After one month of training, testing 
showed an average inter rater reproducibility of 3.8 % and an intra rater 
reproducibility of 1.8 %. 
An example of this technique is shown in Figure 3.1 
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In paper I, we calculated total volume of WMH in each subject, and performed group 
and regression analyses as described in the article.  
 
In paper II, binarized WMH masks, were used to eliminate voxels of misclassified 
WMH, from the gray matter segmented images (please see section 3.4.3.2 VBM). 
 
Figure 3.1  
Axial FLAIR scans (upper raw) and correspondent lesions masks (lower raw) are 
presented, showing WMH contoured with Java Image Manipulation software.  
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In paper III, we investigated the spatial distribution and the total volume of WMH, 
and in this study we performed voxel-wise statistics of WMH masks in addition to 
standard statistical models including the total WMH volumes. Our voxel-wise 
approach can be summarized as follows:  First, we co-registered all FLAIR images to 
the Montreal Neurological Institute standard-space image (MNI152 template) using a 
12-parameter affine model via the FLIRT163 linear registration tool developed by The 
Analysis Group at the Oxford Centre for Functional  MRI of the Brain (FMRIB). The 
resulting transformation matrices were then applied to the corresponding WMH mask 
images to bring these into the same standard space. Prior to statistical comparison, all 
standard-space WMH mask images were smoothed using a Gaussian kernel with a 
standard deviation of 4 mm. Voxel values were then used as dependent variables in a 
mass-univariate application of the general linear model to address spatial-specific 
group differences and to assess the relationship between attention-executive functions 
and spatially specific presence of WMH within the total PD sample. Statistical 
significance was assessed using non-parametric permutation testing,164 and we used 
the threshold-free cluster enhancement technique rather than the more standard a 
priori specification of a cluster forming threshold.165 
 
3.4.3 Brain volume analyses 
In the following section, I will give an overview over the volumetric methods used. 
Due to the complexity of the theories underlying them, and the fact that it would be 
beyond the scope of this thesis, I will and cannot describe them in detail. Specific 
information can be found in the reference literature of each method. 
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3.4.3.1 SIENAX 
FMRIB has developed many methods for analysis of neuroimaging data. The 
majority of their techniques can be freely downloaded from FMRIB’s Software 
Library (FSL) (http://www.fmrib.ox.ac.uk/fsl).163 
 
Included in FSL are FMRIB’s tools for brain change analysis, both for longitudinal 
and cross-sectional studies.  SIENA (Structural Image Evaluation, using 
Normalization, of Atrophy) provides a quantitative method for estimation of intra-
subject temporal change in brain size, and SIENAX is the cross-sectional version of 
the software used for atrophy measurements between subjects at a single time 
point.166 In our initial unselected investigation of our ParkWest MRI cohort (paper I) 
we used SIENAX as a tool for estimations of global atrophy changes in incident PD 
patients compared to control subjects. SIENAX is fast and fully automated. Both 
SIENAX and SIENA was developed with a focus on robustness and the software has 
been shown to perform well also using different MRI field strengths, scanners and 
slice thickness.166 SIENAX provides us with information regarding global brain size 
changes. Such changes may reflect widespread tissue loss or could be a result of 
localised processes. SIENAX is thus an efficient method for estimations of degree of 
degeneration, but it cannot establish regional extent of changes.  
Briefly SIENAX consists of the following steps: 
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1. Deskulling of the brain using Brain Extraction Tool (BET), also part of FSL,167 
resulting in a brain and skull output from each image. 
 
2. Registration and normalization of the individual brain and skull images to MNI152 
standard space using FLIRT.168 Here the brain is used for initial registration and final 
translation and rotation, and the skull is used for scaling and skew optimization. 
 
3. Applying dilated standard MNI152 brainmask in order to optimize deskulled 
output. 
 
4. Tissue segmentation and bias correction of original deskulled brain (gray matter, 
white matter, and CSF) using FMRIB's Automated Segmentation Tool (FAST).169 
Segmentation volumes are then multiplied by a volumetric scaling factor derived 
from the normalization procedure to give rise to normalized brain volumes. 
 
5. Volumes are reported normalized to skull using normalization parameters derived 
from the registration process, and can now be used in statistical quantitative analyses. 
 
In our analyses we applied FSL version 3.3.11, including SIENAX 2.4, BET 2.1 and 
FLIRT 5.4.2. Group analyses compared global tissue volumes between controls and 
patients with PD, and using multiple regression analyses we investigated the impact 
of MRI volumes on cognition in PD. 
An example of the SIENAX segmentation output is given in Figure 3.2. 
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3.4.3.2 Voxel based morphometry  
We used VBM in our MRI analyses of regional gray matter atrophy in paper II.  
VBM is an automated technique consisting of a few main steps:170-172  
 
1. The MRI scans are segmented into gray matter, white matter and CSF, bias 
corrected and transformed into stereotactic space by a computerized algorithm. 
Coronal T1 weighted 3D MRI (left) and corresponding SIENAX 
gray/white matter/CSF mask segmentation (right).  
Figure 3.2  
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2. Segmented tissue masks are smoothed in order to increase statistical validity by 
rendering data more normally distributed and reducing the effective number of 
statistical comparisons. Furthermore, smoothing compensates for the nonexact nature 
of the spatial normalization. 
 
3. Voxel by voxel statistical analysis is performed. Standard VBM approach 
evaluates changes in tissue concentration and/or volumes (on modulated images) 
using parametric statistics within the framework of the general linear model. 
 
For our study we performed VBM using SPM5, (http:// www.fil.ion.ucl.ac.uk/spm) 
running under MATLAB 7.4.0 (R2007a), (Mathworks, Natick, MA). We applied a 
modified unified segmentation procedure170 VBM method (http://dbm.neuro.uni-
jena.de/vbm) adjusted to take into consideration WMH that could be wrongly 
classified as gray matter.173 Such WMH correction was recently highly recommended 
in studies with an elderly population.174  
 
 We first created study- and site-specific tissue priors modified to eliminate the 
possible influence of WMH on gray matter segmentation. 3D-T1 images were first 
normalized to the MNI152 template. During this step, the images were weighted by 
their WMH to exclude the lesions from the normalization procedure (nulling the 
WMH and setting the remaining to 1). Because of the elderly study sample, we did 
not use the MNI tissue probability maps priors in this first segmentation. The 
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segmentation process resulted in gray matter-, white matter- and CSF-segmented 
images for each subject. Normalized gray matter, white matter and CSF images were 
then again conditionally averaged (areas of WMH were not included). The resulting 
gray matter, white matter and CSF-averaged images were smoothed with an 8-mm 
full-width at half-maximum (FWHM) gaussian kernel and used as tissue probability 
maps during the final image segmentation. 
 
3D-T1 images were again segmented in native space into gray matter-, white matter- 
and CSF-segmented images, using the study-specific tissue priors. During the 
normalization step, all images were again weighted by their WMH masks. 
Afterwards, normalized WMH masks were applied to the segmented images to 
remove possible remaining misclassified voxels.  And then, finally, modulated gray 
matter images were smoothed with an 8-mm full with a FWHM gaussian kernel. 
 
Gray matter volumes were compared between groups (MCI PD vs. non-MCI PD, 
MCI PD vs. controls and non-MCI PD vs. controls) using a factorial design 
controlling for total intracranial volume and UPDRS III (PD only). For all analyses 
we used a 1 -1 contrast, in addition to a reverse -1 1 contrast. We also performed 
regression analyses (+1 contrast) between gray matter volumes in the total PD sample 
and cognitive domain performances (memory, visuospatial and attention-executive) 
Statistical significance level was set at a height threshold of p<0.05 false discovery 
rate correction. 
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3.4.3.3 FreeSurfer. 
FreeSurfer is a freely available software application developed at the Athinoula A. 
Martinos Center for Biomedical Imaging (www.nmr.mgh.harvard.edu/martinos). It 
consists of a set of tools for automatic reconstruction of the brain’s cortical surface 
and volumetric segmentation from structural MRI data 
(www.surfer.nmr.mgh.harvard.edu). The reconstructed brain surface can be used in 
combination with functional MRI data, but is also used for measurements of cortical 
thickness related to neurological diseases and as a tool for understanding of brain 
development and function. 
 
We applied FreeSurfer (version 3.2) in order to investigate the degree of subcortical 
atrophy in our newly diagnosed PD patients. This method gives detailed volumetric 
data of a number of brain structures: cerebral white matter, cerebral cortex, ventral 
diencephalon, lateral ventricle, inferior lateral ventricle, cerebellum white matter, 
cerebellar cortex, thalamus, caudate, putamen, pallidum, hippocampus, amygdala, 
accumbens area, third ventricle, fourth ventricle, brain stem and CSF. 
The subcortical segmentation process is described in a detailed methodological 
publication.175 Initially, the T1 weighted MRI scan is registered to the Talairach 
space,176 and the brain is segmented from non-brain tissue using a hybrid algorithm 
combining watershed algorithms and deformable surface models.177 The next stage is 
an initial volume labelling followed by correction of inhomogeneities in the magnetic 
field followed by a non-linear volumetric alignment to Talairach space. After this pre 
processing, the final volume labelling is performed. This step is based on both subject 
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specific intensity values and prior information from a subject- independent 
probabilistic atlas based on a manually labelled training set. Each voxel in the 
brainmask is assigned a label according to its relationship with the label atlas, its 
spatial relation with neighbour labels and its measured intensity. In Paper IV, we 
performed group comparisons of the subcortical volumes using multivariate analysis 
of covariance statistics (MANCOVA) controlling for total intracranial volume, age 
and gender. 
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4. Results 
 
Paper I 
We investigated the extent of whole brain, global gray matter and white matter 
atrophy and total WMH volume, and found that our unselected cohort of patients with 
PD did not differ significantly from controls. Furthermore, we showed that none of 
the MRI measurements were significant predictors of neither global cognition nor 
specific cognitive domains (attention-executive, memory and visuospatial) in PD. 
 
Paper II. 
Aiming to investigate if MCI in patients with early PD was characterized by region-
specific gray matter atrophy, group analyses comparing patients with and without 
MCI and controls showed no regional gray matter tissue differences. We also showed 
that there were no significant correlations between reduced local gray matter volume 
and impaired cognitive test performance. 
 
Paper III 
In this paper we showed that there were no significant differences between the 
control subjects and PD patients with or without MCI with respect to total volume or 
spatial distribution of WMH. In addition, there was no significant relationship 
between total volume or spatial distribution of WMH and attention-executive 
functions in patients with PD.  
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Paper IV 
We found that patients with PD and MCI had significantly larger fourth ventricle, 
third ventricle and left inferior lateral ventricle volumes than controls. Compared to 
patients without MCI, left inferior lateral and third ventricular volumes were 
significantly larger in patients with MCI. The difference in fourth ventricular volume 
did not reach statistical significance, but we showed that volume of fourth ventricle 
was significantly correlated with cognitive performance only in PD patients 
presenting MCI and not in cognitively intact patients or controls. No other significant 
MRI subcortical volume group differences were found.  
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5. Discussion 
 
5.1 Main findings 
 
1. There was no significant loss of whole brain, total gray matter or total white matter 
volumes in newly diagnosed patients with PD compared to age-and sex matched 
control subjects (paper I).  
 
2. There was no significant local gray matter atrophy in newly diagnosed patients 
with PD when comparing with elderly subjects without PD, irrespectively if patients 
with PD were presenting MCI or not (paper II). 
 
3. Total whole brain, gray matter, white matter and lateral ventricular volumes were 
no significant predictors of global cognition in patients in early PD when controlling 
for possible confounders, especially age (paper I).  
 
4. Localized gray matter volume was not significantly correlated with memory, 
visuospatial or attention-executive function when controlling for age, sex, education 
and motor severity (paper II).  
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5. Total lateral ventricular volume was larger, but only trend significant (p=0.059), in 
patients with PD compared to controls (paper I), but a subgroup analysis of patients 
with MCI showed significantly larger fourth, third and left inferior lateral ventricular 
volumes compared to controls and larger third and left inferior lateral ventricle 
compared to patients with no MCI (paper IV). Differences in fourth ventricular 
volume are illustrated in Figure 5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coronal Freesurfer segmentation output of A) normal healthy control (Female, 65 years, 
fourth ventricle volume 2.23 ml) and B) patient with Parkinson’s disease classified as 
having mild cognitive impairment (Female, 68 years, fourth ventricle volume 2.77 ml) 
demonstrating differences in fourth ventricle volume. 
Color legend: pink – gray matter; white – left cerebral white matter; neon green – right 
cerebral white matter; gray – brain stem; yellow – hippocampus; light green – thalamus, 
violet – lateral ventricles; light blue- caudate; brown – cerebellum gray matter; light 
brown – cerebellum white matter; dark green - fourth ventricle. 
 
Figure 5.1  
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6. Total WMH volume was not significantly increased in patients with PD compared 
to controls, and total WMH volume was not a significant predictor of global 
cognition in PD (paper I).  
 
7. Total volume or regional WMH distribution was not significantly different in 
patients with PD (both with and without MCI) than in controls, and neither higher 
total WMH volume nor WMH spatial distribution was significantly associated with 
reduced attention/executive performance in patients with PD (paper III).  
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5.2 Methodology 
 
5.2.1 Study design 
The ParkWest study10 is a population based study, and this design offers several 
advantages to clinic-based studies. The ParkWest study aims to include all residents 
with incident PD in the study area and in this way capture the full spectrum of 
incident PD. This is in contrast to hospital-based studies, often including more 
severely affected patients and thus introducing a potential selection bias.  
 
Our study is a multi centre study, a challenging design with respect to both planning 
and execution of the study protocol. Careful training and regular meeting of involved 
personnel has been conducted to secure a high level of both intra- and inter-centre 
validity. Still, use of different MRI scanners is shown to affect volumetric analyses 
with as much as 10 times.178 In the ParkWest study, the MRI was done on the same 
scanner in each centre during the entire study period, and a common study imaging 
protocol was used. In order to reduce bias of the multiple scanners, we have 
controlled for centre in articles including all subjects using semi-automated WMH 
analyses and the relatively robust SIENAX method166 (paper I and paper III). For 
paper II, we a priori decided to use data from one centre (Stavanger) due to 
recommendations that VBM should be used for scans acquired with the same 
scanner.171 FreeSurfer is highly dependent on gray and white matter tissue contrast in 
the MRI data (http://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferBeginnersGuide). 
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To avoid centre bias, and based on visual inspection revealing the best imaging 
quality in scans from Stavanger, we only included scans from this centre also in paper 
IV. This has recently been shown to be a good decision; results from an evaluation of 
the FreeSurfer subcortical segmentation performance concluded that results within 
scanner platforms are reliable, but combing data across field strengths and platforms 
introduces a bias.179  
 
The data used for this thesis are the baseline results from the ParkWest study. Cross-
sectional results cannot provide answers on causality, only associations between 
variables of interest. This is thus a limitation of the study, but hopefully the 
longitudinal continuation of the study can provide more and new knowledge about 
both causality and progression of cognitive impairments and brain changes in PD. 
 
 
5.2.2 Selection of the study population 
PD is a clinical diagnosis, and the definite diagnosis according to Gelb et al.28 can 
only be made through histopathological examinations post mortem. Idiopathic PD 
may be difficult to diagnose in early stages. In this study, the diagnosis of PD was 
given by specialists in movement disorders to improve diagnostic accuracy.180 Before 
the final diagnosis, patients had about two years of clinical follow-up and repeated 
examinations. Known differential diagnoses, e.g. dementia with Lewy bodies, were 
carefully excluded with as much confidence as possible in early disease based on 
current criteria. Still, we cannot be 100 % confident that some patients with time may 
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end up with diagnoses such as Progressive Supranuclear Palsy and Multiple System 
Atrophy. 
 
Control subjects were selected based on age and sex and recruited from spouses and 
friends of the patients and in this way provide the same socioeconomic and cultural 
background. Diagnoses with high prevalence in the elderly, e.g. cerebrovascular 
disease, were not exclusion criteria in order in order to recruit a control/reference 
cohort with similar co-morbidity as observed in the general population. Thus, the 
findings in our study likely reflect differences between representative groups of 
patients with PD and elderly subjects.  
 
With respect to the MRI cohort there are a few issues that deserve to be discussed. 
All patients were intended to have a MRI scan, but due to MRI contraindications and 
poor health, an examination could not be performed in some subjects. This may have 
introduced biases. One potential bias could be exclusion of patients with 
cardiovascular disease potentially resulting in WMH, due to pacemaker being a 
contraindication of MRI. Still, we believe this is a minor issue in our cohort since 
statistical comparison of patients with and without MRI showed no significant 
difference in vascular risk (rated as presence of one or more of the following: 
hypertension, diabetes mellitus, hypercholesterolemia, atrial fibrillation, peripheral 
vascular disease, coronary heart disease, previous stroke or current smoking), p 
=0.217, Pearson Chi-Square. Furthermore, patients without MRI could potentially be 
older subjects with more advanced disease (motor and/or cognition) making the MRI 
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examination an impossible task. We do find that patients without an MRI scan are 
older (mean age 73 years vs. 67 years, independent samples t-test p=0 .003), have 
higher UPDRS III score (mean 29.1 vs. 22.4, Mann-Whitney test p= 0.024) and H&Y 
stage (mean 2.2 vs.1.9, Mann-Whitney test p= 0.051), but total MMSE score did not 
differ significantly (26.9 vs. 27.7 Mann-Whitney test p= 0.188).  
 
A potential caveat may also be subjects excluded as a result of major MRI artefacts. 
Good quality scans are dependent on that subjects are able to lie still in the scanner. It 
is therefore also possible that subjects excluded due to movement artefacts are older 
patients with more advanced disease. Similar selection bias is introduced by technical 
software factors since segmentation of subjects with major atrophy may fail (due to 
registration and normalisation errors), and these subjects are left out of the statistical 
analyses. As an illustrations of this is presented in paper I, where we showed that 
patients with unacceptable SIENAX segmentations (some due to major atrophy 
experienced by visual inspection) were somewhat older than patients with acceptable 
segmentations.  
 
In general, exclusion of subjects is unfortunate and should be avoided as it results in 
reduced power in addition to the potential biases mentioned above. Still, we believe 
that this is unavoidable given the population based nature of the study and the know 
limitations of the MRI technique and today’s analysing methods. 
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5.2.3 Neuropsychological assessment 
The neuropsychological evaluations used for this work has several advantages. The 
tests were chosen because they are believed to be little affected by motor 
impairments, and the majority of patients were tested before they started anti-
dopaminergic treatment. Furthermore, the cognitive classifications were done taking 
age, sex and education under consideration, and whenever possible using published 
research criteria, e.g. for dementia in PD.44 A possible criticism of the cognitive 
aspects of this research is the rather limited neuropsychological test battery.  
 
The MCI approach in the ParkWest study needs to be validated.64 As mentioned in 
section 1.1.6.2, there is at present time no established MCI classification in PD.  As a 
result of different methodology and sensitivity of applied neuropsychological tests, 
frequency of MCI differs among previous incident cohorts. 62-65 A previous long-term 
follow-up study of PD patients with MCI indicates that MCI, especially certain 
subtypes, is a risk factor of PDD.181 The prognostic value of the MCI classifications 
needs important validation through longitudinal research, and it will thus be very 
interesting to follow the ParkWest study cohort in the next 10 years.  
 
Much work is currently investigated in defining standardized diagnostic MCI criteria 
in PD, and several task forces are working on the subject (D. Årsland, personal 
communication). Potential differences lie in the choice of number and type of 
neuropsychological tests and in the cut-off applied to define impairments compared 
to controls. In the near future, collaborative effort and validation studies will 
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hopefully result in guidelines available for new clinical studies and meta-analyses. 
Standardized MCI criteria are also of utmost importance for future imaging studies in 
this field of research. Neuroimaging may be used as a tool in investigations of the 
underlying pathology causing the heterogeneous clinical expressions of MCI in PD. 
Depending on the outcomes of studies, imaging can potentially become a valuable aid 
in future clinical drug trials aiming to improve deficits or delay progression of 
cognitive dysfunction in patients with PD. 
 
5.2.4 Brain volumetric methods 
Volumetric MRI in research is used to estimate extent of tissue loss and brain 
morphometry in normal brains as well as in pathological conditions. Loss of brain 
tissue (i.e. atrophy) is regarded as the end stage of neurodegeneration. Volumetric 
MRI is used as a biomarker in studies of Alzheimer’s disease148 and multiple 
sclerosis.182 Recently 3D patterns of MRI atrophy were validated as a surrogate 
marker of the neurodegenerative aspects of AD atrophy correlating with 
neurofibrillary tangle pathology.183 In PD research, the usefulness of such 
investigations is not yet established. Analyses of newly diagnosed patients potentially 
provide information about the extent of pathological processes very early in the 
disease. Neuropathological studies in newly diagnosed patients are sparse. MRI 
studies investigating atrophy in early PD are therefore necessary to increase our 
understanding of how the brain pathology acts and develops, knowledge important in, 
for example, future drug trials aiming to prevent tissue loss.  
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Despite potential advantages, there are a few general methodological issues to be 
addressed regarding volumetric brain MRI analyses. As discussed in section 5.2.1, 
several technical factors should be considered when planning and executing studies 
since accuracy of results is influenced by image quality, technical protocols and use 
of different MRI scanners.178 In our study we have tried to take this into account, and 
when choosing methods for testing of our hypotheses, we had to consider the 
robustness of the software in addition to the quality of the MRI data.  
 
We applied automated volumetric MRI methods, and thus minimized operator 
dependent biases possibly affecting previous manual ROI studies. Still, it is well 
known for especially VBM, that results may vary considerably based on 
methodological options available for analysing parameters like smoothing filter 
size184 and normalization template.185,186 Our adapted VBM approach is thoroughly 
described in section 3.4.3.2. The rationale for our decisions was based on established 
reference literature,171 and previous comparable research173 in addition to web site 
advices by Dr. C. Gaser, a leading expert in MRI morphometry (http://dbm.neuro.uni-
jena.de/vbm). Options also exist for the presentation of significant anatomic labels 
resulting from VBM studies. We decided to present our results according to 
Brodmann area and the Talairach and Tournoux atlas,176 similar to comparable 
previous studies, e.g. Beyer et al.123 We recognize that this approach has been 
criticised given its inaccuracy and may be suboptimal.187 
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In addition to the above issues regarding methodology, biological factors are also 
known to influence the outcomes of atrophy studies, e.g. normal aging.97 A 
discussion of age as a potential confounder is recommended when reporting MRI 
studies,172 and is accordingly included in all the included papers of this thesis. 
 
The exact biological basis of morphometric brain changes are not known.84 At present 
a histopathological validation of the volumetric MRI findings in PD is lacking, and 
we can therefore not be sure what is causing the previously reported brain volume 
changes. A recent study by Burton et al. investigated the pathological correlates of 
medial temporal lobe atrophy in subjects with histological verified diagnoses of AD, 
DLB and vascular cognitive impairment.188 The study reports that of 23 subjects with 
DLB, nine had PD clinically for more than one year prior to development of the 
psychiatric features of DLB. In their sample they found that medial temporal lobe 
atrophy was a significant predictor of AD tangle pathology, but not Lewy body like-
inclusions in the hippocampus. The cellular substrate for the morphometric brain 
changes previously reported in patients with PD may thus represent pathology 
beyond the Lewy bodies diagnostic of the disease. These are very interesting 
findings, and more studies comparing antemortem MRI scans and histopathology are 
highly needed. 
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5.2.5 WMH evaluation  
We have used a well known semi-automated method for estimation of WMH load. 
This method differs from most previous WMH studies in PD using semi-quantitative 
rating scales.85,88,89 As described in section 1.2.5 these scales may have some 
limitations, and comparison of different methods has shown that visual scoring is less 
sensitive than volumetric assessment.90 We did not have techniques available for fully 
automatic WMH lesion estimations, but believe that our semi-automatic method and 
especially the voxel-wise comparison approach is a methodological improvement 
compared to previous studies.  
 
5.2.6 Statistics 
For statistical comparisons of demographic and clinical data, we have employed 
generally accepted methods according to the distribution of data. We have used a 
standard, but rather liberal, statistical significance threshold in all papers (p<0.05) 
given the explorative nature of our work. Our studies are among the first population 
based structural MRI studies of patients with early PD and should provide hypotheses 
for future research. If more conservative thresholds were to be used, this would 
inflate the risk of making type II errors and thus potentially limit generation of such 
new hypotheses. Although this explorative approach, we have considered and taken 
into account important issues regarding thresholding and statistical methods of voxel-
based statistics. Voxel-based MRI analyses are mass-univariate based including large 
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numbers of statistical comparisons, and results should therefore be controlled for 
multiple comparisons.172 In both our voxel-based papers (paper II and III), we have 
addressed this, and results are accordingly corrected for multiple comparisons. 
 
We are aware that our non-significant volumetric findings could be a result of 
underpowered analyses, especially in group analyses of paper II and IV including 
only subjects from one centre. As stated in the papers, results must therefore be 
interpreted with caution. Still, our sample size is comparable to previous and current 
studies in the field. The limited sample size is especially evident for our MCI group, 
and we were not able to perform any MCI subgroup analyses. The characteristics of a 
small heterogeneous MCI group might be difficult to depict, but still results from 
paper IV indicate that mesocortex, brainstem and midbrain pathology might be a 
common trait of MCI in newly diagnosed PD. Future studies should, if possible, 
include more subjects especially given the limited expected effect size.189 
 
In all our volumetric analyses we have corrected for the impact of aging on brain 
morphometry. Given the potential special role of age on disease progression in PD, 
this issue needs to be discussed in detail. As mentioned, prevalence studies report a 
clear relationship between age and PD, and the disease is rare in people under 50 
years of age.8 Studies have found that advancing age is associated with faster rate of 
motor impairment, decreased levodopa responsiveness, more severe gait and postural 
impairment and more severe cognitive dysfunction.13 If age interacts with disease 
specific neurodegenerative processes in PD, as suggested by Levy et al.,13 correcting 
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for age in statistical models might remove disease specific findings. In volumetric 
brain MRI studies of neurodegenerative diseases, age correction is necessary to 
establish effects not being a result of normal aging.  Taken together, these factors 
represent another future challenge in PD imaging research. We have not been able to 
address this statistically in the presented papers, and a probability might therefore 
exist that we have removed disease specific brain changes when correcting for age.  
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5.3 Results 
 
5.3.1 WMH 
We found no significant association between WMH and cognition in PD. In addition, 
we did not show any significant difference in volume and distribution of WMH in 
patients with PD compared to age-matched controls. These results therefore indicate 
that vascular brain pathology is not a major contributor to the cognitive dysfunctions 
seen in newly diagnosed patients PD. Our findings are thus in line with a previous 
clinical observation study from our group claiming that there is no association 
between cerebrovascular risk factors and incident dementia in PD.23  
 
Results in paper III are somewhat in conflict with an earlier study from our group 
regarding WMH in patients with PD.144 In this paper, Beyer and colleagues found that 
demented patients with PD had significantly more WMH in frontal, periventricular 
and deep white matter compared to non-demented patients. The differences were 
driven by lower levels of WMH in non-demented patients than control subjects, and 
the combined PD group was not significantly from different from controls with 
respect to WMH. The semi-quantitative rating scale used in this former study is 
different from our quantitative volumetric approach, but our voxel-wise analyses on 
regional distribution of WMH should be a good method for detection of significant 
distribution differences of WMH in patients with PD and various degree of cognitive 
dysfunction. 
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An important consideration in the interpretation of our WMH findings is that the 
previous works include older patients with longer disease duration. It is thus possible 
that development of age-associated WMH will have more impact on cognition as the 
disease progresses, at least in some subjects.  
 
Our results do indicate higher lesion load in patients with PD and MCI compared to 
patients with no MCI and controls, but the difference did not reach statistical 
significance. It is possible that analysis of various MCI subgroups would provide 
information about the extent of vascular pathology in the different aspects of MCI in 
early PD, but this was not performed in the present study and could be an interesting 
topic for future studies. 
 
We found significantly increased frequency of diabetes mellitus in our MCI group 
(paper III). Diabetes mellitus is a risk factor for WMH progression,190 and it will be 
very interesting to investigate how the WMH progression relates to the various 
vascular risk factors in the cognitive subgroups of the ParkWest study. Even though 
WMH was not a significant contributor to cognitive dysfunction at present time, only 
longitudinal follow-up can provide answers to how cardiovascular risk, baseline 
WMH volume and age will impact WMH progression and cognitive status in our PD 
cohort as the disease progresses.  
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5.3.2 Brain volume analyses 
5.3.2.1 Whole brain, total gray matter and total white matter volumes 
Results from global brain atrophy analyses (i.e. SIENAX166) reflect the degree of 
widespread neurodegenerative pathology leading to loss of brain tissue. Our analyses 
did not reveal any significant group differences between our unselected incident PD 
cohort and age-matched controls. These results thus suggest that in newly diagnosed 
patients with PD, widespread atrophy is limited. This is in line with previous studies 
including smaller samples of patients with PD.109,112 Still, pathology may be present 
not reflected by our method, as indicated in a diffusion study of early PD.109 
Furthermore, local gray matter changes may exist in such a degree or distribution that 
it is not reflected using global volume estimations. 
 
5.3.2.2 Ventricular volume analyses 
Cerebral ventricular volume analyses provide an indirect measure of brain atrophy. 
Our relatively crude global methods cannot estimate potential regional pathology in 
detail. But findings, if present, may provide indications of such, generate hypotheses 
and motivate future studies. In paper I, normalized lateral ventricular volume was the 
variable showing largest difference between patients and controls, with a trend 
towards significantly increased volume in patients with PD. This finding could be a 
sign of pathology in surrounding brain, possibly on a regional basis as indicated in 
Cordato et al.126 A recent study showed a strong relationship between asymmetric 
lateral ventricular enlargement and PD motor asymmetry and progression.191 Future 
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studies should investigate the various aspects of lateral ventricular morphology in 
patients with PD as a marker of brain tissue pathology.  
 
We were able to detect significant differences between patients with PD and MCI and 
controls with respect to fourth ventricular, third and left inferior lateral volumes. We 
choose to interpret also this as a possible indirect sign of pathology in adjacent brain. 
Comparing patients with and without MCI, we showed significant differences in third 
and left inferior lateral volumes. Enlargement of fourth ventricular volume could 
therefore be a disease specific sign rather than pathology related to cognitive 
impairment. Still we chose to interpret the strong correlations between memory 
performance and fourth ventricular volume only within the MCI group, as indications 
of a role of brainstem pathology also in cognitive dysfunctions in newly diagnosed 
PD. Interestingly, a recent study also found brain stem atrophy in a sample of patients 
with early PD.130 Again, the studies could be in line with the Braak hypothesis,32  but 
as discussed above in section 1.1.4 the validity of this hypothesis is debated, and 
more research is clearly needed. 
 
5.3.2.3 Regional gray matter volume analyses 
We looked for regional gray matter changes using VBM in a subgroup of our 
patients, and we were unable to detect significant changes in patients compared to 
controls irrespectively if they were presenting MCI or not. In the correlation analyses, 
cognitive test performance was not significantly associated with localized gray matter 
volume. Our results are somewhat different previous comparable studies,123,134 but as 
 109 
described in paper II, we believe that the conflicting results can be explained by a 
number of factors. First, our patients were less cognitively impaired with a higher 
MMSE score. Secondly, previous studies included samples of older subjects with 
longer disease duration and more advanced PD than in our current study. Thirdly, all 
three studies were based on small cohorts. Given the clinical and pathological 
heterogeneity in PD,5 small sample sizes may lead to different findings. These 
factors, in addition to important methodological differences in MRI analysis and MCI 
classification, are likely to explain the conflicting results. We believe that our present 
findings, with the limitations of a relatively small cohort especially for the group 
analyses, provide us with important new knowledge of how to investigate the 
biological basis for early cognitive changes in PD. Our VBM study indicated that the 
neurodegenerative process underlying PD at this stage is subtle. In the years to come, 
research aiming to detect the cerebral pathology in newly diagnosed, and preferably 
premotor, PD has to continue the search for neuroimaging techniques able to 
visualize such discrete cerebral changes.  
  
Our FreeSurer analysis in paper IV was in line with the VBM analysis, and none of 
the subcortical gray matter volumes were significantly different between groups. This 
is different from previous ROI based studies of early non-demented patients with 
PD.110,114,121 We did find smaller volumes in PD patients compared to controls in 
most of the examined structures, so an explanation of the non-significant findings 
could again lie in a possible lack of power. 
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5.3.3 Clinical implications 
Our results provide knowledge regarding the potential impact of vascular brain 
changes and cognitive dysfunction in PD. Based on our work there is little evidence 
that prevention and control of WMH risk factors will reduce the frequencies of 
cognitive impairment in early clinical stages. Still, given our cross-sectional design, 
results of causality cannot be drawn, and results must therefore be interpreted with 
caution.  
 
Findings from our atrophy studies suggests that the degree of tissue loss in early PD 
(with and without cognitive impairment) is less than shown in for instance AD, and 
the clinical use of conventional structural MRI in PD is therefore still limited to 
exclusion of differential diagnoses. Our results, and previous published papers in the 
field, may indicate a certain degree of pathology on a group level and provide 
hypotheses for future research, but at present the individual diagnostic value is very 
limited.  
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6. Conclusion and future directions 
 
The lack of significant global atrophy findings in early PD is not surprising given 
results from previous smaller studies, but we have now replicated the findings in our 
large population based sample of patients. Work included in this thesis provides more 
knowledge about PD, contrary to for instance AD, as a disease with little tissue loss 
in early disease stages. Results on tissue specific and subcortical atrophy are limited 
by a possible lack of power, but altogether our findings could indicate brain 
pathology in accordance with the Braak hypothesis.152 This needs to be investigated 
in future studies including larger cohorts and preferably longitudinal designs.  
 
All our findings must be seen in the light of contemporary, similar studies 
investigating other neurodegenerative disease with known associated cognitive 
dysfunction. At present time, structural MRI in PD does not seem to be the most 
potent potential imaging biomarker, but the reason for this might be that most 
previous studies have used methods validated against AD.  Based on our preliminary 
results, future studies searching for the biological basis for cognitive dysfunction in 
early PD should also focus on developing imaging techniques and analysis methods 
for better investigation of brainstem and midbrain.  
 
Furthermore, a shift of focus from mainly investigations of gray matter pathology to 
studies investigating white matter atrophy and disruptions of white matter integrity 
could contribute important knowledge as indicated by recent findings in Martin et 
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al.129 This also needs to be explored in the years to come. We have investigated the 
association between total white matter volume, ventricular size (an indirect measure 
of white matter atrophy) and WMH and cognition in early PD, but potential sources 
for new information could, for instance, be more use of diffusion MRI of white 
matter tracts in the brain. In general, combining various imaging parameters (e.g. 
morphometry, diffusion and functional techniques) may result in new knowledge and 
increased diagnostic sensitivity of MCI in PD, as recently shown in a multimodal 
imaging study of MCI in AD.192 
 
An interesting focus for future studies lies in exploring the various cognitive and 
motor subtypes in PD. As clinical and histopathological research are giving us more 
and more information about the disease heterogeneity in patients with PD, the 
neuroimaging community needs to approach this and search for a biological basis for 
the clinical expressions. This can be accomplished in large, longitudinal population 
based studies, and our hope is that future investigations of the ParkWest cohort can 
bring us closer to fulfilling this aim. 
 
To the best of our knowledge, our work is the first in analyzing MRI scans of patients 
with early PD using various volumetric methods. In the years ahead, more studies of 
this kind would be valuable in the exploration of MRI detectable pathology in PD 
brains. Volumetric MRI findings should preferably be compared to post mortem 
atrophy studies and histopathological findings (although we acknowledge that this is 
often not available in early disease stages). In this way, the sensitivity and validity of 
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the various volumetric tools could be established, essential knowledge for future 
work in this field of science. 
  
A final comment regarding future structural MRI research, especially voxel-based, is 
emphasizing the need for consistent reporting and methodology.172 This is valuable 
especially when comparing findings from various studies. Previous studies reported 
their results using a wide spectrum of thresholds and methods, often in small sample 
sizes. These studies were all very important and timely exploratory work and 
generated hypotheses for future studies. Now, in common effort, we all need to 
continue our search for MRI detectable pathology in a comparable manner using 
recommended guidelines, e.g. the recent VBM recommendations.172 
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